JP2005060314A - Cosmetic - Google Patents
Cosmetic Download PDFInfo
- Publication number
- JP2005060314A JP2005060314A JP2003293045A JP2003293045A JP2005060314A JP 2005060314 A JP2005060314 A JP 2005060314A JP 2003293045 A JP2003293045 A JP 2003293045A JP 2003293045 A JP2003293045 A JP 2003293045A JP 2005060314 A JP2005060314 A JP 2005060314A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- peptide
- pro
- gly
- cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 83
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 320
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 162
- 229920001184 polypeptide Polymers 0.000 claims abstract description 154
- 230000000694 effects Effects 0.000 claims abstract description 34
- 229920000742 Cotton Polymers 0.000 claims abstract description 33
- 239000007787 solid Substances 0.000 claims abstract description 20
- 239000007788 liquid Substances 0.000 claims abstract description 19
- 238000001142 circular dichroism spectrum Methods 0.000 claims abstract description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 6
- 150000001413 amino acids Chemical class 0.000 claims description 41
- 125000000539 amino acid group Chemical group 0.000 claims description 17
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- 102000029816 Collagenase Human genes 0.000 claims description 7
- 108060005980 Collagenase Proteins 0.000 claims description 7
- 229960002424 collagenase Drugs 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 abstract description 27
- 102000008186 Collagen Human genes 0.000 abstract description 27
- 229920001436 collagen Polymers 0.000 abstract description 27
- 208000015181 infectious disease Diseases 0.000 abstract description 9
- 230000001717 pathogenic effect Effects 0.000 abstract description 8
- 244000052769 pathogen Species 0.000 abstract description 7
- 230000005540 biological transmission Effects 0.000 abstract description 6
- -1 Val or Ala Chemical compound 0.000 description 83
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- 239000003795 chemical substances by application Substances 0.000 description 46
- 235000002639 sodium chloride Nutrition 0.000 description 39
- 239000000243 solution Substances 0.000 description 35
- 239000002585 base Substances 0.000 description 34
- 238000000034 method Methods 0.000 description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 229920005989 resin Polymers 0.000 description 23
- 239000011347 resin Substances 0.000 description 23
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- 239000008363 phosphate buffer Substances 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 18
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 16
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical class C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 16
- 238000002523 gelfiltration Methods 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 15
- 238000005227 gel permeation chromatography Methods 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- 238000005755 formation reaction Methods 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 239000003480 eluent Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000009833 condensation Methods 0.000 description 11
- 230000005494 condensation Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 239000000178 monomer Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 239000000654 additive Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 210000004209 hair Anatomy 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 230000000704 physical effect Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 7
- 238000009739 binding Methods 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 238000010532 solid phase synthesis reaction Methods 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000012505 Superdex™ Substances 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 229960003767 alanine Drugs 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 6
- 239000003906 humectant Substances 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229960002429 proline Drugs 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 102000029797 Prion Human genes 0.000 description 5
- 108091000054 Prion Proteins 0.000 description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 150000005846 sugar alcohols Chemical class 0.000 description 5
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 241000024188 Andala Species 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 206010014970 Ephelides Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006482 condensation reaction Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 230000000475 sunscreen effect Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 3
- LFTRJWKKLPVMNE-RCBQFDQVSA-N 2-[[(2s)-2-[[2-[[(2s)-1-[(2s)-2-amino-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-methylbutanoyl]amino]acetic acid Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O LFTRJWKKLPVMNE-RCBQFDQVSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 239000004264 Petrolatum Substances 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 210000003298 dental enamel Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 150000003949 imides Chemical class 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 239000001023 inorganic pigment Substances 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 108010054022 valyl-prolyl-glycyl-valyl-glycine Proteins 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- XQQUSYWGKLRJRA-RABCQHRBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-methylbutanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XQQUSYWGKLRJRA-RABCQHRBSA-N 0.000 description 2
- MWOGMBZGFFZBMK-LJZWMIMPSA-N (2s)-2-[[(2s)-2-[[2-[[(2s,3s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWOGMBZGFFZBMK-LJZWMIMPSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920002567 Chondroitin Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical class COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- HXKZJLWGSWQKEA-LSJOCFKGSA-N His-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1 HXKZJLWGSWQKEA-LSJOCFKGSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- 108010027234 aspartyl-glycyl-glutamyl-alanine Proteins 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000010696 ester oil Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 239000003676 hair preparation Substances 0.000 description 2
- 239000008269 hand cream Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 108010088381 isoleucyl-lysyl-valyl-alanyl-valine Proteins 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000010445 mica Substances 0.000 description 2
- 229910052618 mica group Inorganic materials 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000011356 non-aqueous organic solvent Substances 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229940109850 royal jelly Drugs 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 2
- 229920001187 thermosetting polymer Polymers 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
- 108010052768 tyrosyl-isoleucyl-glycyl-seryl-arginine Proteins 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- 150000003752 zinc compounds Chemical class 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 1
- IZKGGDFLLNVXNZ-KRWDZBQOSA-N (2s)-5-amino-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)N)C(O)=O)C3=CC=CC=C3C2=C1 IZKGGDFLLNVXNZ-KRWDZBQOSA-N 0.000 description 1
- WTKQMHWYSBWUBE-UHFFFAOYSA-N (3-nitropyridin-2-yl) thiohypochlorite Chemical compound [O-][N+](=O)C1=CC=CN=C1SCl WTKQMHWYSBWUBE-UHFFFAOYSA-N 0.000 description 1
- 125000006681 (C2-C10) alkylene group Chemical group 0.000 description 1
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BZSXSIQTILQTNQ-SCWOKBSMSA-N (prolyl-hydroxylprolyl-glycine)10 Chemical compound N1([C@@H](C[C@H](C1)O)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](C[C@@H](O)C1)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](C[C@@H](O)C1)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](C[C@@H](O)C1)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](C[C@@H](O)C1)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](C[C@@H](O)C1)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](C[C@@H](O)C1)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](C[C@@H](O)C1)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](C[C@@H](O)C1)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](C[C@@H](O)C1)C(=O)NCC(O)=O)C(=O)C1CCCN1 BZSXSIQTILQTNQ-SCWOKBSMSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FNQIGYRDLYROLW-UHFFFAOYSA-N 1-hydroxy-2h-1,2,3-benzotriazine Chemical class C1=CC=C2N(O)NN=CC2=C1 FNQIGYRDLYROLW-UHFFFAOYSA-N 0.000 description 1
- FQKFPGMGQXQHLP-UHFFFAOYSA-N 1-hydroxytriazole Chemical class ON1C=CN=N1 FQKFPGMGQXQHLP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- RZRILSWMGXWSJY-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;sulfuric acid Chemical compound OS(O)(=O)=O.OCCN(CCO)CCO RZRILSWMGXWSJY-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- HJBLUNHMOKFZQX-UHFFFAOYSA-N 3-hydroxy-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)N=NC2=C1 HJBLUNHMOKFZQX-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241001237961 Amanita rubescens Species 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 1
- VENMDXUVHSKEIN-GUBZILKMSA-N Arg-Ser-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VENMDXUVHSKEIN-GUBZILKMSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052582 BN Inorganic materials 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- PZNSFCLAULLKQX-UHFFFAOYSA-N Boron nitride Chemical compound N#B PZNSFCLAULLKQX-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 239000004640 Melamine resin Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- GLLSGHWYBGERSE-UHFFFAOYSA-N [2-(hydroxymethoxy)phenyl]-phenylmethanone;sodium Chemical compound [Na].OCOC1=CC=CC=C1C(=O)C1=CC=CC=C1 GLLSGHWYBGERSE-UHFFFAOYSA-N 0.000 description 1
- WXIONIWNXBAHRU-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylidene]-dimethylazanium Chemical compound C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 WXIONIWNXBAHRU-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 125000005263 alkylenediamine group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229940089116 arnica extract Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000004009 axon guidance Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940073609 bismuth oxychloride Drugs 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- QHIWVLPBUQWDMQ-UHFFFAOYSA-N butyl prop-2-enoate;methyl 2-methylprop-2-enoate;prop-2-enoic acid Chemical compound OC(=O)C=C.COC(=O)C(C)=C.CCCCOC(=O)C=C QHIWVLPBUQWDMQ-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000011538 cleaning material Substances 0.000 description 1
- 229940080423 cochineal Drugs 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical compound C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PGRLPHKGHMCNGH-UHFFFAOYSA-N dodecanoic acid ethanol Chemical compound CCO.CCO.CCCCCCCCCCCC(O)=O PGRLPHKGHMCNGH-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- XRLCQRMNGQRGOC-MDZDMXLPSA-N ethyl (e)-3-[2,4-di(propan-2-yl)phenyl]prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC=C(C(C)C)C=C1C(C)C XRLCQRMNGQRGOC-MDZDMXLPSA-N 0.000 description 1
- LCFXLZAXGXOXAP-UHFFFAOYSA-N ethyl 2-cyano-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(=NO)C#N LCFXLZAXGXOXAP-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000002143 fast-atom bombardment mass spectrum Methods 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- DWYMPOCYEZONEA-UHFFFAOYSA-L fluoridophosphate Chemical compound [O-]P([O-])(F)=O DWYMPOCYEZONEA-UHFFFAOYSA-L 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 229940074774 glycyrrhizinate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229960002350 guaiazulen Drugs 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- XYSJYAQKIAGPFT-UHFFFAOYSA-N heptatriacontan-19-ylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCC([NH3+])CCCCCCCCCCCCCCCCCC XYSJYAQKIAGPFT-UHFFFAOYSA-N 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000003915 liquefied petroleum gas Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229940105112 magnesium myristate Drugs 0.000 description 1
- DMRBHZWQMKSQGR-UHFFFAOYSA-L magnesium;tetradecanoate Chemical compound [Mg+2].CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O DMRBHZWQMKSQGR-UHFFFAOYSA-L 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- PVWXTVUZGJXFJQ-UHFFFAOYSA-N methyl 4-methyl-3-phenyl-2-propan-2-ylpent-2-enoate Chemical compound COC(=O)C(C(C)C)=C(C(C)C)C1=CC=CC=C1 PVWXTVUZGJXFJQ-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940074096 monoolein Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229960003921 octisalate Drugs 0.000 description 1
- FFZFHRYMHDWKAX-UHFFFAOYSA-N octyl 2-aminobenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1N FFZFHRYMHDWKAX-UHFFFAOYSA-N 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- XOEUGELJHSUYGP-UHFFFAOYSA-N octyl 4-aminobenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=C(N)C=C1 XOEUGELJHSUYGP-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910052628 phlogopite Inorganic materials 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920006122 polyamide resin Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001225 polyester resin Polymers 0.000 description 1
- 239000004645 polyester resin Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920005672 polyolefin resin Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- QAZCPUUJMFBNJO-UHFFFAOYSA-N pyrrolidin-2-one;sodium Chemical compound [Na].O=C1CCCN1 QAZCPUUJMFBNJO-UHFFFAOYSA-N 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical group C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229920006268 silicone film Polymers 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- XUXNAKZDHHEHPC-UHFFFAOYSA-M sodium bromate Chemical compound [Na+].[O-]Br(=O)=O XUXNAKZDHHEHPC-UHFFFAOYSA-M 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical class NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229920005992 thermoplastic resin Polymers 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
- 125000003508 trans-4-hydroxy-L-proline group Chemical group 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 229920006337 unsaturated polyester resin Polymers 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本発明は、病原体感染の危険性が無く、安全性の高いコラーゲン様ポリペプチドを含む化粧料に関する。 The present invention relates to a cosmetic comprising a collagen-like polypeptide that has no risk of pathogen infection and is highly safe.
コラーゲンは、あらゆる多細胞動物にみられる繊維状蛋白質であり、皮膚や骨の主成分として哺乳類では全蛋白質の25%を占める。典型的なコラーゲン分子は、3本のコラーゲンポリペプチド鎖が三重らせん構造と呼ばれるロープ状の超らせん構造をとる。上記3重らせん構造を形成したポリペプチド鎖が自己集合して、直径が数nm〜数十nmの原線維を形成し、さらにこれらの原線維が配列して直径が数μm〜数十μmの繊維構造を形成することができる。 Collagen is a fibrous protein found in all multicellular animals and accounts for 25% of the total protein in mammals as the main component of skin and bone. A typical collagen molecule has a rope-like superhelical structure in which three collagen polypeptide chains are called a triple helical structure. The above-mentioned polypeptide chains having a triple helical structure self-assemble to form fibrils having a diameter of several nanometers to several tens of nanometers, and these fibrils are arranged to have a diameter of several micrometers to several tens of micrometers. A fiber structure can be formed.
また、コラーゲンは、高い保湿効果を有しており、基礎化粧料、メークアップ用化粧料などを始め、多くの化粧料用途で広く用いられている。一般に、化粧品ではウシやブタ由来のコラーゲンを原料として用いることが多い。中でも、牛由来のコラーゲンは、物理化学的特性に優れ、原料臭が少ないため多用されてきた。 Collagen has a high moisturizing effect and is widely used in many cosmetic applications including basic cosmetics and makeup cosmetics. Generally, cosmetics often use bovine or porcine collagen as a raw material. Among them, bovine-derived collagen has been widely used because of its excellent physicochemical properties and low raw material odor.
しかし、哺乳動物由来コラーゲンに対する危険性が指摘されている。例えば、ウシの海綿状脳症やヒツジの振戦病の原因物質が、プリオンと呼ばれる伝染性蛋白質であり、この伝染性タンパク質がヒトのクロイツフェルドーヤコブ病伝染の原因の一つと言われている。プリオンは、蛋白質であり、通常の滅菌、殺菌方法では失活し難く、しかも種を越えて感染することが指摘されている(Nature Review, Vol.2, pp.118-126, 2001年(非特許文献1))。そのため、通常の滅菌、殺菌方法では除去できないプリオンなどの病原体(又は病原性因子)の感染(又は伝達)の危険性が常に存在している。 However, a danger to mammal-derived collagen has been pointed out. For example, the causative substance of bovine spongiform encephalopathy and sheep tremor is an infectious protein called prion, and this infectious protein is said to be one of the causes of human Creutzfelder-Jakob disease. Prion is a protein that is difficult to inactivate by normal sterilization and sterilization methods, and has been pointed out to infect across species (Nature Review, Vol.2, pp.118-126, 2001 (non- Patent Document 1)). Therefore, there is always a risk of infection (or transmission) of pathogens (or pathogenic factors) such as prions that cannot be removed by ordinary sterilization and sterilization methods.
このような病原体の感染の危険性を回避するため、特開平08−041425号公報(特許文献1)には、動物又は人間由来のコラーゲン中のプリオンを除去するために、コラーゲン溶液中の細胞および組織の断片を除去し、アルカリ処理する方法およびこの方法により得られるコラーゲンが記載されている。しかし、このような方法は、安全性の確認を必要とし、煩雑でコスト高となる。 In order to avoid the risk of such pathogen infection, Japanese Patent Application Laid-Open No. 08-041425 (Patent Document 1) describes cells and cells in collagen solutions in order to remove prions in animal or human collagen. A method of removing tissue fragments and treating with alkali and a collagen obtained by this method are described. However, such a method requires confirmation of safety, and is complicated and expensive.
牛由来コラーゲンなどの代替品として、魚類由来のコラーゲンなどが提案されている。例えば、 特開2001−302690号公報(特許文献2)には、牛や豚などの骨、皮、腱、あるいは魚皮由来のコラーゲン成分又はゼラチン成分を、コラゲナーゼ酵素を用いて特異的に分解して得られる特定のアミノ酸配列を有するトリペプチドが、高い皮膚浸透性を有し、化粧品などの外用剤として有用であることが開示されている。 As an alternative to cattle-derived collagen, fish-derived collagen has been proposed. For example, Japanese Patent Application Laid-Open No. 2001-302690 (Patent Document 2) specifically decomposes a collagen component or gelatin component derived from bone, skin, tendon, or fish skin of cows or pigs using a collagenase enzyme. It is disclosed that a tripeptide having a specific amino acid sequence obtained in this way has high skin permeability and is useful as an external preparation such as cosmetics.
しかし、魚類由来のコラーゲンでは、化粧料の組成などによっては異臭を発生する場合がある。特開2003−146835号公報(特許文献3)では、魚由来のコラーゲンと親油化処理粉体とシリコーンとを含有する化粧料において、コラーゲン上にシリコーンの被膜を形成することにより、異臭の発生を防いでいる。しかし、このような方法では、コラーゲンの周囲に被膜が形成されているため、コラーゲンの保湿力を有効利用できない。また、粉体が必須であるため、用途が限られる。 However, in collagen derived from fish, an off-flavor may be generated depending on the composition of the cosmetic. In Japanese Patent Application Laid-Open No. 2003-146835 (Patent Document 3), in cosmetics containing fish-derived collagen, lipophilic powder and silicone, generation of off-flavor is caused by forming a silicone film on collagen. Is preventing. However, in such a method, since a film is formed around the collagen, the moisturizing power of the collagen cannot be effectively used. Moreover, since powder is essential, the use is limited.
また、天然のコラーゲン中には種々の細胞接着サイトが含まれているため、用途に応じた細胞選択性が発揮できない。例えば、神経の軸索誘導材料としてコラーゲンを用いると、軸索の伸長速度より周囲の繊維芽細胞の遊走、増殖速度が大きく瘢痕組織化して軸索が伸長することができない。このため、繊維芽細胞の遊走を防ぐ材料でコラーゲンの周囲を覆うことなどの措置が必要となる。
従って、本発明の目的は、コラーゲンの優れた特性を有しながらも、病原体の感染や病原性因子の伝達を生じる危険性がなく、安全性の高い化粧料を提供することにある。 Accordingly, an object of the present invention is to provide a highly safe cosmetic that has the excellent properties of collagen but does not have the risk of causing infection by pathogens or transmission of pathogenic factors.
本発明の他の目的は、保湿性及び安定性が高く、臭気を生じさせることのない化粧料を安価に提供することにある。 Another object of the present invention is to provide a cosmetic that has high moisture retention and stability and does not cause odor at a low cost.
本発明者らは、前記課題を達成するため鋭意検討した結果、特定の合成ポリペプチドがコラーゲン様の特性を有し、高い保湿性及び安定性を有することを見いだし、本発明を完成した。 As a result of intensive studies to achieve the above-mentioned problems, the present inventors have found that a specific synthetic polypeptide has collagen-like characteristics, high moisturizing properties and stability, and completed the present invention.
すなわち、本発明の化粧料は、ポリペプチドを含む化粧料であって、前記ポリペプチドは少なくとも式Pro-Y-Gly(式中、YはProまたはHypを表す)で表されるアミノ酸配列を有し、かつコラーゲン様の構造を形成する合成ポリペプチドで構成されている。前記ポリペプチドは、下記式(1)〜(3) で表されるペプチドユニットで構成されたポリペプチド(I)、および及び下記式(4)で表されるアミノ酸配列を有するペプチドユニットと、下記式(5)で表されるアミノ酸配列を有するペプチドユニットとを含むポリペプチド(II)から選択された少なくとも一種のポリペプチドであってもよい。 That is, the cosmetic of the present invention is a cosmetic containing a polypeptide, and the polypeptide has at least an amino acid sequence represented by the formula Pro-Y-Gly (wherein Y represents Pro or Hyp). And a synthetic polypeptide that forms a collagen-like structure. The polypeptide includes a polypeptide (I) composed of peptide units represented by the following formulas (1) to (3), and a peptide unit having an amino acid sequence represented by the following formula (4): It may be at least one polypeptide selected from the polypeptide (II) containing a peptide unit having the amino acid sequence represented by the formula (5).
[-(OC-(CH2)m-CO)p-(Pro-Y-Gly)n-]a (1)
[-(OC-(CH2)m-CO)q-(Z)r-]b (2)
[-HN-R-NH-]c (3)
(式中、mは1〜18の整数、p及びqは同一又は異なって0又は1、YはProまたはHypを表し、nは1〜20の整数を表す。Zは1〜10個のアミノ酸残基からなるペプチド鎖を表し、rは1〜20の整数を表し、Rは直鎖状又は分岐鎖状アルキレン基を表す。aとbとの割合(モル比)はa/b=100/0〜30/70であり、p=1及びq=0であるときc=a、p=0及びq=1であるときc=bであり、p=1及びq=1であるときc=a+bであり、p=0及びq=0であるときc=0である)。
[-(OC- (CH 2 ) m -CO) p- (Pro-Y-Gly) n- ] a (1)
[-(OC- (CH 2 ) m -CO) q- (Z) r- ] b (2)
[-HN-R-NH-] c (3)
(In the formula, m is an integer of 1 to 18, p and q are the same or different and 0 or 1, Y represents Pro or Hyp, n represents an integer of 1 to 20. Z represents 1 to 10 amino acids. Represents a peptide chain comprising residues, r represents an integer of 1 to 20, R represents a linear or branched alkylene group, and the ratio (molar ratio) between a and b is a / b = 100 / 0 = 30/70, c = 1 when p = 1 and q = 0, c = b when p = 0 and q = 1, c = when p = 1 and q = 1 a + b, c = 0 when p = 0 and q = 0).
-Pro-Y-Gly- (4)
(式中、Yは前記に同じ)
-Pro-V-Gly-W-Ala-Gly- (5)
(式中、VはGln、Asn、Leu、Ile、ValまたはAla、WはIleまたはLeuを表す)。
-Pro-Y-Gly- (4)
(Where Y is the same as above)
-Pro-V-Gly-W-Ala-Gly- (5)
(In the formula, V represents Gln, Asn, Leu, Ile, Val or Ala, and W represents Ile or Leu).
前記ポリペプチド(I)において、mは2〜12の整数、nは2〜15の整数、Zは、Gly、Sar、Ser、Glu、Asp、Lys、His、Ala、Val、Leu、Arg、Pro、Tyr、Ileから選択された1〜10個のアミノ酸残基からなるペプチド鎖、rは1〜10の整数、RはC2-12アルキレン基であってもよい。 In the polypeptide (I), m is an integer of 2 to 12, n is an integer of 2 to 15, Z is Gly, Sar, Ser, Glu, Asp, Lys, His, Ala, Val, Leu, Arg, Pro , Tyr, or Ile, a peptide chain consisting of 1 to 10 amino acid residues, r may be an integer of 1 to 10, and R may be a C 2-12 alkylene group.
さらに、ペプチドユニット(4)とペプチドユニット(5)との割合(モル比)は、(4)/(5)=99/1〜30/70程度であってもよい。 Further, the ratio (molar ratio) between the peptide unit (4) and the peptide unit (5) may be about (4) / (5) = 99/1 to 30/70.
前記ポリペプチドは、通常、円二色性スペクトルにおいて、波長220〜230nmに正のコットン効果を示し、波長195〜205nmに負のコットン効果を示す。このことは、ポリペプチドの少なくとも一部(一部または全部)が、3重らせん構造を形成することを示している。本発明のポリペプチドは、分子量5×103〜500×104の範囲にピークを示してもよい。さらに、前記ポリペプチドは、生体内で分解し吸収される生体内分解性ポリペプチドであってもよい。すなわち、ポリペプチドはコラゲナーゼ分解性を有していてもよい。 The polypeptide usually exhibits a positive cotton effect at a wavelength of 220 to 230 nm and a negative cotton effect at a wavelength of 195 to 205 nm in a circular dichroism spectrum. This indicates that at least a part (part or all) of the polypeptide forms a triple helical structure. The polypeptide of the present invention may exhibit a peak in the molecular weight range of 5 × 10 3 to 500 × 10 4 . Furthermore, the polypeptide may be a biodegradable polypeptide that is degraded and absorbed in vivo. That is, the polypeptide may have collagenase degradability.
前記化粧料は、粉末状化粧料、固形又は半固形状化粧料、あるいは液状化粧料であってもよい。 The cosmetic may be a powder cosmetic, a solid or semi-solid cosmetic, or a liquid cosmetic.
本発明の化粧料は、コラーゲン様特性を有する特定の合成ポリペプチドを含むため、コラーゲンの優れた特性を有するにも拘わらず、病原体の感染や病原性因子の伝達を生じる危険性がなく、安全性が高い。また、保湿性及び安定性が高く、臭気を生じさせることがない。さらにポリペプチドを合成により得ることができるため、化粧料を安価に提供できる。 Since the cosmetic of the present invention contains a specific synthetic polypeptide having collagen-like properties, it has no risk of causing infection of pathogens or transmission of pathogenic factors, despite having excellent properties of collagen, and is safe. High nature. Moreover, it has high moisture retention and stability and does not cause odor. Furthermore, since a polypeptide can be obtained by synthesis, cosmetics can be provided at low cost.
[ポリペプチド]
本発明においては各種アミノ酸残基を次の略号で記述する。
[Polypeptide]
In the present invention, various amino acid residues are described by the following abbreviations.
Ala :L−アラニン残基
Arg :L−アルギニン残基
Asn :L−アスパラギン残基
Asp :L−アスパラギン酸残基
Cys :L−システイン残基
Gln :L−グルタミン残基
Glu :L−グルタミン酸残基
Gly :グリシン残基
His :L−ヒスチジン残基
Hyp :L−ヒドロキシプロリン残基
Ile :L−イソロイシン残基
Leu :L−ロイシン残基
Lys :L−リジン残基
Met :L−メチオニン残基
Phe :L−フェニルアラニン残基
Pro :L−プロリン残基
Sar :サルコシン残基
Ser :L−セリン残基
Thr :L−トレオニン残基
Trp :L−トリプトファン残基
Tyr :L−チロシン残基
Val :L−バリン残基
また、本明細書においては、常法に従って、N末端のアミノ酸残基を左側に位置させ、C末端のアミノ酸残基を右側に位置させて、ペプチド鎖のアミノ酸配列を記述する。
Ala: L-alanine residue
Arg: L-arginine residue
Asn: L-asparagine residue
Asp: L-aspartic acid residue
Cys: L-cysteine residue
Gln: L-glutamine residue
Glu: L-glutamic acid residue
Gly: Glycine residue
His: L-histidine residue
Hyp: L-hydroxyproline residue
Ile: L-isoleucine residue
Leu: L-leucine residue
Lys: L-lysine residue
Met: L-methionine residue
Phe: L-phenylalanine residue
Pro: L-proline residue
Sar: Sarcosine residue
Ser: L-serine residue
Thr: L-threonine residue
Trp: L-tryptophan residue
Tyr: L-tyrosine residue
Val: L-valine residue In this specification, according to a conventional method, the amino acid sequence of the peptide chain is determined by positioning the N-terminal amino acid residue on the left side and the C-terminal amino acid residue on the right side. Describe.
本発明の化粧料は、コラーゲン様の構造を形成する前記特定の合成ポリペプチドで構成されている。このポリペプチドは、少なくとも式Pro-Y-Gly(式中、YはPro又はHypを示す)で表されるアミノ酸配列を有している。前記アミノ酸配列は、3重らせん構造の安定性に寄与するため、前記ポリペプチドは、コラーゲン組織(コラーゲン状の組織)又はコラーゲン様の構造を形成する限り種々のポリペプチドが使用できる。このようなポリペプチドには、前記ポリペプチド(I)と前記ポリペプチド(II)とが含まれる。 The cosmetic of the present invention is composed of the specific synthetic polypeptide that forms a collagen-like structure. This polypeptide has at least an amino acid sequence represented by the formula Pro-Y-Gly (wherein Y represents Pro or Hyp). Since the amino acid sequence contributes to the stability of the triple helical structure, various polypeptides can be used as the polypeptide as long as it forms a collagenous tissue (collagenous tissue) or a collagen-like structure. Such a polypeptide includes the polypeptide (I) and the polypeptide (II).
前記ポリペプチド(I)において、構成するペプチドユニット(1) [-(OC-(CH2)m-CO)p-(Pro-Y-Gly)n-]は、Pro-Y-Glyの繰返し配列を含むことが必要である。Pro-Y-Glyの繰返し数が、少ないと3重らせん構造の安定性が減少し、繰返し数が多すぎるとペプチドの合成が困難になる。従って、繰返し数nは、1〜20、好ましくは2〜15(例えば、3〜15)、さらに好ましくは5〜15程度である。 In the polypeptide (I), the constituting peptide unit (1) [-(OC- (CH 2 ) m -CO) p- (Pro-Y-Gly) n- ] is a repetitive sequence of Pro-Y-Gly. It is necessary to include. When the number of Pro-Y-Gly repeats is small, the stability of the triple helical structure decreases, and when the number of repeats is too large, synthesis of the peptide becomes difficult. Therefore, the repeating number n is 1 to 20, preferably 2 to 15 (for example, 3 to 15), more preferably about 5 to 15.
前記式(1)において、Yは、Pro又はHypいずれであってもよいが、3重らせん構造の安定性からHypであるのがより好ましい。なお、Hypは、通常、4Hyp(例えば、trans−4−ヒドロキシ−L−プロリン)残基である。 In the formula (1), Y may be either Pro or Hyp, but more preferably Hyp from the viewpoint of the stability of the triple helical structure. Hyp is usually a 4Hyp (eg, trans-4-hydroxy-L-proline) residue.
さらに、メチレン鎖(CH2)の繰り返し数を示すmは、ポリペプチドの物理的及び生物学的性質を損なわない範囲であればよいが、通常、1〜18、好ましくは2〜12、さらに好ましくは2〜10(特に2〜6)程度である。pは0又は1である。 Further, m indicating the number of repeating methylene chains (CH 2 ) may be in a range that does not impair the physical and biological properties of the polypeptide, but is usually 1 to 18, preferably 2 to 12, and more preferably. Is about 2 to 10 (particularly 2 to 6). p is 0 or 1.
前記ペプチドユニット(2)[-(OC-(CH2)m-CO)q-(Z)r-]において、Zは1〜10個のアミノ酸残基で構成された任意の配列のペプチド鎖を表す。Zは、得られるポリペプチドの物理的及び生物学的性質を損なわない限り、どのような配列でもよい。ポリペプチドが有用な物理的及び生物学的性質を発揮するためには、例えば、ペプチド鎖Zは、通常、Gly、Sar、Ser、Glu、Asp、Lys、His、Ala、Val、Leu、Arg、Pro、Tyr、Ileから選択された1〜10個のアミノ酸残基からなるペプチド鎖(すなわち、これらのアミノ酸から選択されたアミノ酸残基、又はこれらのアミノ酸から選択された2〜10個のアミノ酸残基からなるペプチド鎖)、特に、Gly、Sar、Ser、Glu、Asp、Lys、Arg、Pro、Valから選択された1〜10個のアミノ酸残基からなるペプチド鎖を有している場合が多い。ペプチド鎖Zは、Gly、Sar、Ser、Glu、Asp、Lys、Arg-Gly-Asp、Tyr-Ile-Gly-Ser-Arg、Ile-Lys-Val-Ala-Val、Val-Pro-Gly-Val-Gly、Asp-Gly-Glu-Ala、Gly-Ile-Ala-Gly、His-Ala-Val、Glu-Arg-Leu-Glu、Lys-Asp-Pro-Lys-Arg-Leu、Arg-Ser-Arg-Lysで示される配列を含むのが好ましい。 In the peptide unit (2) [-(OC- (CH 2 ) m -CO) q- (Z) r- ], Z represents a peptide chain of an arbitrary sequence composed of 1 to 10 amino acid residues. Represent. Z may be any sequence as long as the physical and biological properties of the resulting polypeptide are not impaired. In order for a polypeptide to exhibit useful physical and biological properties, for example, the peptide chain Z is typically Gly, Sar, Ser, Glu, Asp, Lys, His, Ala, Val, Leu, Arg, Peptide chain consisting of 1 to 10 amino acid residues selected from Pro, Tyr, and Ile (that is, amino acid residues selected from these amino acids, or 2 to 10 amino acid residues selected from these amino acids) Peptide chain consisting of a group), in particular, often has a peptide chain consisting of 1 to 10 amino acid residues selected from Gly, Sar, Ser, Glu, Asp, Lys, Arg, Pro, Val . Peptide chain Z is Gly, Sar, Ser, Glu, Asp, Lys, Arg-Gly-Asp, Tyr-Ile-Gly-Ser-Arg, Ile-Lys-Val-Ala-Val, Val-Pro-Gly-Val -Gly, Asp-Gly-Glu-Ala, Gly-Ile-Ala-Gly, His-Ala-Val, Glu-Arg-Leu-Glu, Lys-Asp-Pro-Lys-Arg-Leu, Arg-Ser-Arg It is preferable to include the sequence represented by -Lys.
ペプチド鎖Zの繰り返し数を示すrは、得られるポリペプチドが物理的及び生物学的性質を発揮する範囲であればよい。繰返し数rが多すぎると合成が困難になり、また得られるポリペプチドの物理的性質が変化しやすい。従って、繰返し数rは、通常、1〜20、好ましくは1〜10、さらに好ましくは1〜5程度である。 R indicating the number of repetitions of the peptide chain Z may be in a range where the obtained polypeptide exhibits physical and biological properties. If the number of repetitions r is too large, synthesis becomes difficult and the physical properties of the resulting polypeptide are likely to change. Therefore, the repeating number r is usually about 1 to 20, preferably about 1 to 10, and more preferably about 1 to 5.
メチレン鎖(CH2)の繰り返し数を示すmは、前記式(1)と同様に、1〜18、好ましくは2〜12、さらに好ましくは2〜10(特に2〜6)程度である。qは0又は1である。 M showing the number of repetitions of the methylene chain (CH 2), like the equation (1), 18, preferably 2 to 12, more preferably 2 to 10 (particularly 2-6) about. q is 0 or 1.
前記式(1)及び(2)において、p及びqのうち少なくとも一方が1であるとき、ポリペプチドは、前記式(3)で表されるユニット[-HN-R-NH-]を含んでいる。この前記式(3)で表されるユニットにおいて、Rで表される直鎖状又は分岐鎖状アルキレン基は、ポリペプチドの物理的及び生物学的性質を損なわない範囲であればよく、例えば、メチレン、エチレン、プロピレン、トリメチレン、テトラメチレンなどのC1-18アルキレン基が例示できる。前記アルキレン基Rは、直鎖状のメチレン鎖(CH2)s(sは1〜18の整数を表す)であってもよい。好ましいRは、C2-12アルキレン基(さらに好ましくはC2-10アルキレン基,特にC2-6アルキレン基)である。 In the formulas (1) and (2), when at least one of p and q is 1, the polypeptide contains a unit [—HN—R—NH—] represented by the formula (3). Yes. In the unit represented by the formula (3), the linear or branched alkylene group represented by R may be in a range that does not impair the physical and biological properties of the polypeptide. Examples thereof include C 1-18 alkylene groups such as methylene, ethylene, propylene, trimethylene and tetramethylene. The alkylene group R may be a linear methylene chain (CH 2 ) s (s represents an integer of 1 to 18). Preferred R is a C 2-12 alkylene group (more preferably a C 2-10 alkylene group, particularly a C 2-6 alkylene group).
前記式(1)で表されるペプチドユニットと前記式(2)で表されるペプチドユニットとの割合(a/b)は、100/0〜30/70(モル比)、好ましくは100/0〜40/60(モル比)、さらに好ましくは100/0〜50/50(モル比)程度である。 The ratio (a / b) between the peptide unit represented by the formula (1) and the peptide unit represented by the formula (2) is 100/0 to 30/70 (molar ratio), preferably 100/0. It is about 40/60 (molar ratio), more preferably about 100/0 to 50/50 (molar ratio).
さらに、前記式(3)で表されるユニットの割合は、前記式(1)のpの値、前記式(2)のqの値に応じて選択でき、p=1及びq=0であるとき、c=aであり、p=0及びq=1であるとき、c=bである。また、p=1及びq=1であるときc=a+bであり、p=0及びq=0であるときc=0である。 Furthermore, the ratio of the unit represented by the formula (3) can be selected according to the value of p in the formula (1) and the value of q in the formula (2), and p = 1 and q = 0. When c = a and when p = 0 and q = 1, c = b. Also, when p = 1 and q = 1, c = a + b, and when p = 0 and q = 0, c = 0.
すなわち、前記ポリペプチド(I)には、(a)前記式(1)でp=0であるペプチドユニット[-(Pro-Y-Gly)n-]の繰り返し単位で構成されたポリペプチド、(b)前記式(1)でp=0であるペプチドユニット[-(Pro-Y-Gly)n-]と前記式(2)でq=0であるペプチドユニット[-(Z)r-]とをa:bの割合(モル%)で含む繰り返し単位で構成されたポリペプチド、(c)前記式(1)でp=1であるペプチドユニット[-(OC-(CH2)m-CO)-(Pro-Y-Gly)n-]と前記式(3)で表されるユニット[-HN-R-NH-]とを1:1の割合(モル比)で含む繰り返し単位で構成されたポリペプチド、(d)前記式(1)でp=1であるペプチドユニット[-(OC-(CH2)m-CO)-(Pro-Y-Gly)n-]と前記式(2)でq=1であるペプチドユニット[-(OC-(CH2)m-CO)-(Z)r-]と前記式(3)で表されるユニット[-HN-R-NH-]とをa:b:a+bの割合(モル比)で含む繰り返し単位で構成されたポリペプチドが含まれる。 That is, the polypeptide (I) includes (a) a polypeptide composed of repeating units of the peptide unit [-(Pro-Y-Gly) n- ] in which p = 0 in the formula (1), b) a peptide unit [-(Pro-Y-Gly) n- ] in which p = 0 in the formula (1) and a peptide unit [-(Z) r- ] in which q = 0 in the formula (2); (C) a peptide unit [-(OC- (CH 2 ) m -CO) wherein p = 1 in the above formula (1) -(Pro-Y-Gly) n- ] and the unit [-HN-R-NH-] represented by the above formula (3) at a ratio (molar ratio) of 1: 1. (D) a peptide unit [-(OC- (CH 2 ) m -CO)-(Pro-Y-Gly) n- ] wherein p = 1 in the formula (1) and the formula (2) q = 1 and is a peptide unit and a unit represented by the formula (3) [-HN-R- NH-] [- (OC- (CH 2) m -CO) - - (Z) r] : B: include polypeptides comprised of repeating units in a proportion of a + b (molar ratio).
一方、前記ポリペプチド(II)は、-Pro-Y-Gly-で表されるアミノ酸配列を有するペプチドユニット(4)を含むことが必要である。-Pro-Y-Gly-で表される配列は、3重らせん構造の安定性に寄与するため、この配列の割合が少ないと3重らせん構造の安定性が減少する。 On the other hand, the polypeptide (II) needs to contain a peptide unit (4) having an amino acid sequence represented by -Pro-Y-Gly-. Since the sequence represented by -Pro-Y-Gly- contributes to the stability of the triple helix structure, the stability of the triple helix structure decreases when the proportion of this sequence is small.
さらに、このユニット(4)は、3重らせん構造の安定性の点から、ポリペプチド中において、-(Pro-Y-Gly)d-で表される繰返し構造を形成してもよい。この配列の繰返し数dは、例えば、2〜5000、好ましくは2〜4000、さらに好ましくは3〜3000程度である。Yは、ProまたはHypのいずれであってもよいが、前記と同様に、3重らせん構造の安定性からHyp[通常、4Hyp(例えば、trans−4−ヒドロキシ−L−プロリン)残基]であるのがより好ましい。 Furthermore, this unit (4) may form a repeating structure represented by-(Pro-Y-Gly) d -in the polypeptide from the viewpoint of the stability of the triple helical structure. The repeating number d of this arrangement is, for example, about 2 to 5000, preferably 2 to 4000, and more preferably about 3 to 3000. Y may be either Pro or Hyp, but in the same manner as described above, it is Hyp [usually 4Hyp (for example, trans-4-hydroxy-L-proline) residue] because of the stability of the triple helical structure. More preferably.
また、本発明におけるポリペプチド(II)は、-Pro-V-Gly-W-Ala-Gly-で表されるアミノ酸配列を有するペプチドユニット(5)を含むのが有用である。この配列を含まない場合や少なすぎる場合には、コラゲナーゼによる分解性が低下する。一方、この配列が多すぎると3重らせん構造の安定性が低下する。 Moreover, it is useful that the polypeptide (II) in the present invention includes a peptide unit (5) having an amino acid sequence represented by -Pro-V-Gly-W-Ala-Gly-. When this sequence is not included or too little, the degradation by collagenase is reduced. On the other hand, when the number of the sequences is too large, the stability of the triple helical structure is lowered.
VはGln、Asn、Leu、Ile、ValまたはAlaのいずれであってもよいが、Gln、Asn、Leu、Val、Ala、特にGln、Leuがより好ましい。WはIleまたはLeuのいずれでもよいが、Ileがより好ましい。 V may be Gln, Asn, Leu, Ile, Val, or Ala, but Gln, Asn, Leu, Val, Ala, particularly Gln, Leu are more preferable. W may be either Ile or Leu, but Ile is more preferred.
VとWとの組み合わせは、例えば、VがGln、Asn、Leu、Ile、Val及びAlaから選択された一種(例えば、Gln又はLeu)であり、WがIleであるペプチドや、VがGln、Asn、Leu、Ile、Val及びAlaから選択された一種(例えば、Gln又はLeu)であり、WがLeuであるペプチドなどが挙げられる。 The combination of V and W is, for example, a type in which V is selected from Gln, Asn, Leu, Ile, Val and Ala (for example, Gln or Leu), and a peptide in which W is Ile, or V is Gln, Examples thereof include a peptide selected from Asn, Leu, Ile, Val, and Ala (for example, Gln or Leu), and W is Leu.
YとVとWとの組み合わせは、YがHyp、VがGln、Asn、Leu、Ile、Val及びAlaから選択された一種(例えば、Gln又はLeu)、WがIle又はLeuであるペプチドや、YがPro、VがGln、Asn、Leu、Ile、Val及びAlaから選択された一種(例えば、Gln又はLeu)、WがIle又はLeuであるペプチドなどが挙げられる。 A combination of Y, V and W is a peptide in which Y is Hyp, V is Gln, Asn, Leu, Ile, Val and Ala (for example, Gln or Leu), W is Ile or Leu, Examples include a peptide in which Y is Pro, V is Gln, Asn, Leu, Ile, Val and Ala (for example, Gln or Leu), and W is Ile or Leu.
さらに、得られるポリペプチドの物理的及び生物学的性質を損なわない限り、このポリペプチド(II)は他のアミノ酸残基やペプチド鎖(ユニット)を含んでいてもよい。他のアミノ酸残基又はペプチド鎖としては、前記ペプチドユニット(2)の-(Z)r-で表されるペプチド鎖などが挙げられる。すなわち、このポリペプチドが有用な物理的及び生物学的性質を発揮するためには、例えば、Gly、Sar、Ser、Glu、Asp、Lys、His、Ala、Val、Leu、Arg、Pro、Tyr、Ileから選択された1〜10個のアミノ酸残基から構成されているペプチド鎖(すなわち、これらのアミノ酸から選択されたアミノ酸残基、又はこれらのアミノ酸から選択された2〜10個のアミノ酸残基から構成されているペプチド鎖)、特に、Gly、Sar、Ser、Glu、Asp、Lys、Arg、Pro、Valから選択された1〜10個のアミノ酸残基から構成されているペプチド鎖を有している場合が多い。具体的には、例えば、Gly、Sar、Ser、Glu、Asp、Lys、Arg-Gly-Asp、Tyr-Ile-Gly-Ser-Arg、Ile-Lys-Val-Ala-Val、Val-Pro-Gly-Val-Gly、Asp-Gly-Glu-Ala、Gly-Ile-Ala-Gly、His-Ala-Val、Glu-Arg-Leu-Glu、Lys-Asp-Pro-Lys-Arg-Leu、Arg-Ser-Arg-Lysで示されるアミノ酸残基やペプチド鎖を含むのが好ましい。 Furthermore, this polypeptide (II) may contain other amino acid residues and peptide chains (units) as long as the physical and biological properties of the resulting polypeptide are not impaired. Examples of other amino acid residues or peptide chains include peptide chains represented by- (Z) r-in the peptide unit (2). That is, in order for this polypeptide to exhibit useful physical and biological properties, for example, Gly, Sar, Ser, Glu, Asp, Lys, His, Ala, Val, Leu, Arg, Pro, Tyr, A peptide chain composed of 1 to 10 amino acid residues selected from Ile (that is, amino acid residues selected from these amino acids, or 2 to 10 amino acid residues selected from these amino acids) A peptide chain composed of 1 to 10 amino acid residues selected from Gly, Sar, Ser, Glu, Asp, Lys, Arg, Pro, Val There are many cases. Specifically, for example, Gly, Sar, Ser, Glu, Asp, Lys, Arg-Gly-Asp, Tyr-Ile-Gly-Ser-Arg, Ile-Lys-Val-Ala-Val, Val-Pro-Gly -Val-Gly, Asp-Gly-Glu-Ala, Gly-Ile-Ala-Gly, His-Ala-Val, Glu-Arg-Leu-Glu, Lys-Asp-Pro-Lys-Arg-Leu, Arg-Ser It preferably contains an amino acid residue or peptide chain represented by -Arg-Lys.
前記ポリペプチド(II)において、前記ペプチドユニット(4)と前記ペプチドユニット(5)との割合(モル比)は、(4)/(5)=99/1〜30/70、好ましくは98/2〜40/60、さらに好ましくは95/5〜50/50程度である。 In the polypeptide (II), the ratio (molar ratio) between the peptide unit (4) and the peptide unit (5) is (4) / (5) = 99/1 to 30/70, preferably 98 / It is 2-40 / 60, More preferably, it is about 95 / 5-50 / 50.
前記ペプチドユニット(4)及び前記ペプチドユニット(5)の合計量と、他のペプチドユニットとの割合(モル比)は、前者/後者=100/0〜50/50、好ましくは100/0〜60/40、さらに好ましくは100/0〜70/30程度である。 The ratio (molar ratio) between the total amount of the peptide unit (4) and the peptide unit (5) and the other peptide units is the former / the latter = 100 / 0-50 / 50, preferably 100 / 0-60. / 40, more preferably about 100/0 to 70/30.
このようなポリペプチド(I)及び(II)は、環化により6員環を形成することなく、鎖状のポリペプチドを形成しており、溶媒(水、ジメチルスルホキシドなどのスルホキシド類、ジメチルホルムアミド、ジメチルアセトアミド、N-メチルピロリドンなどの親水性溶媒又はそれらの混合溶媒)に可溶である。前記ポリペプチドは、水系ゲルパーミエーションクロマトグラフィー(GPC)において、球状蛋白質換算で、例えば、分子量5×103〜500×104、好ましくは分子量1×104〜300×104、好ましくは3×104〜200×104、さらに好ましくは5×104〜100×104程度の範囲にピークを示す。 Such polypeptides (I) and (II) form a chain-like polypeptide without forming a 6-membered ring by cyclization, and a solvent (water, sulfoxides such as dimethyl sulfoxide, dimethylformamide, etc. , A hydrophilic solvent such as dimethylacetamide and N-methylpyrrolidone or a mixed solvent thereof). The polypeptide is, for example, a molecular weight of 5 × 10 3 to 500 × 10 4 , preferably a molecular weight of 1 × 10 4 to 300 × 10 4 , preferably 3 in terms of globular protein in aqueous gel permeation chromatography (GPC). A peak is shown in the range of about × 10 4 to 200 × 10 4 , more preferably about 5 × 10 4 to 100 × 10 4 .
さらに、これらのポリペプチドは、円二色性スペクトルにおいて、波長220〜230nmに正のコットン効果を示し、波長195〜205nmに負のコットン効果を示す。そのため、ポリペプチドの少なくとも一部(すなわち、一部または全部)が3重らせん構造を形成可能であり、コラーゲン様ポリペプチドを形成する。なお、コットン効果とは、旋光性物質において特定の波長で左右の円偏光に対する吸収係数が異なるために起こる現象をいう。 Furthermore, these polypeptides show a positive cotton effect at wavelengths of 220 to 230 nm and a negative cotton effect at wavelengths of 195 to 205 nm in the circular dichroism spectrum. Therefore, at least a part (that is, part or all) of the polypeptide can form a triple helical structure, forming a collagen-like polypeptide. The cotton effect refers to a phenomenon that occurs because the optical rotation material has different absorption coefficients for left and right circularly polarized light at a specific wavelength.
これらのポリペプチドは、コラーゲン組織(コラーゲン状の組織)を形成可能である。上記3重らせん構造を形成したポリペプチド鎖が自己集合して、数nm〜数十nmの原線維を形成し、さらにこれらの原線維が配列して数nm〜数十nmの繊維構造を形成することができる。これらは、透過型電子顕微鏡、走査型電子顕微鏡、あるいは原子間力顕微鏡により観察することができる。 These polypeptides can form a collagen tissue (collagenous tissue). Polypeptide chains that form the triple helical structure self-assemble to form fibrils of several nm to several tens of nm, and these fibrils are arranged to form a fiber structure of several nm to several tens of nm. can do. These can be observed with a transmission electron microscope, a scanning electron microscope, or an atomic force microscope.
前記ポリペプチド(I)(II)は、生分解性、特に生体内分解性を有していてもよい。このような生分解性ポリペプチドはコラゲナーゼ分解性を有している。特に、前記ポリペプチド(II)は高い生分解性を示す。 The polypeptides (I) and (II) may have biodegradability, particularly biodegradability. Such biodegradable polypeptides have collagenase degradability. In particular, the polypeptide (II) exhibits high biodegradability.
これらのポリペプチドは、生理学的又は薬理学的に許容される塩であってもよく、例えば、無機酸(塩酸、硫酸、リン酸など)、有機酸(酢酸、トリフルオロ酢酸、乳酸、酒石酸、マレイン酸、フマル酸、シュウ酸、リンゴ酸、クエン酸、オレイン酸、パルミチン酸など)、金属(ナトリウム、カリウムなどのアルカリ金属、カルシウムなどのアルカリ土類金属、アルミニウムなど)、有機塩基(トリメチルアミン、トリエチルアミン、t−ブチルアミン、ベンジルアミン、ジエタノールアミン、ジシクロヘキシルアミン、アルギニンなど)との塩であってもよい。これらの塩形成化合物は、単独で又は二種以上組み合わせて使用できる。これらの塩は、通常の塩形成反応によって得ることができる。 These polypeptides may be physiologically or pharmacologically acceptable salts such as inorganic acids (hydrochloric acid, sulfuric acid, phosphoric acid, etc.), organic acids (acetic acid, trifluoroacetic acid, lactic acid, tartaric acid, Maleic acid, fumaric acid, oxalic acid, malic acid, citric acid, oleic acid, palmitic acid, etc., metals (alkali metals such as sodium and potassium, alkaline earth metals such as calcium, aluminum etc.), organic bases (trimethylamine, And a salt with triethylamine, t-butylamine, benzylamine, diethanolamine, dicyclohexylamine, arginine and the like. These salt-forming compounds can be used alone or in combination of two or more. These salts can be obtained by ordinary salt formation reactions.
これらのポリペプチド(I)(II)は、アミノ酸やペプチドセグメントを縮合反応に供する慣用の方法により得ることができ、最終的に前記ユニットがポリペプチド中に含まれている限り特に制限されず、例えば、アミノ酸を縮合反応する方法や、ペプチドセグメントとアミノ酸を縮合する方法により得てもよいが、予め、前記アミノ酸配列を有するペプチド又はその誘導体などのペプチド成分を調製し、このペプチド成分を縮合する方法により得るのが好ましい。 These polypeptides (I) and (II) can be obtained by a conventional method in which amino acids and peptide segments are subjected to a condensation reaction, and are not particularly limited as long as the unit is finally contained in the polypeptide. For example, it may be obtained by a method of condensation reaction of amino acids or a method of condensation of peptide segments and amino acids, but a peptide component such as a peptide having the amino acid sequence or a derivative thereof is prepared in advance, and this peptide component is condensed. It is preferably obtained by a method.
予め調製したペプチド成分を縮合する方法において、ペプチド成分のペプチド鎖の合成は、通常のペプチド合成方法に従って行うことができる。ペプチドは、例えば、固相合成法または液相合成法によって調製できるが、固相合成法が操作上簡便である〔例えば、日本生化学会編「続生化学実験講座2 タンパク質の化学(下)」(昭和62年5月20日 株式会社東京化学同人発行)、第641−694頁参照〕。ペプチド合成には、慣用の方法、例えば、縮合剤を用いるカップリング方法、活性エステル法(p−ニトロフェニルエステル(ONp)、ペンタフルオロフェニルエステル(Opfp)などのフェニルエステル、N−ヒドロキシスクシンイミドエステル(ONSu)などのN−ヒドロキシジカルボン酸イミドエステル、1−ヒドロキシベンゾトリアゾールエステル(Obt)など)、混合酸無水物法、アジド法などが利用できる。好ましい方法では、少なくとも縮合剤(好ましくは後述する縮合剤、特に後述する縮合剤と縮合助剤との組合せ)を用いる場合が多い。 In the method of condensing a peptide component prepared in advance, the peptide chain of the peptide component can be synthesized according to an ordinary peptide synthesis method. The peptide can be prepared, for example, by a solid phase synthesis method or a liquid phase synthesis method. However, the solid phase synthesis method is simple in operation [for example, “Sequence Chemistry Laboratory Lecture 2 Protein Chemistry (Part 2)” (See pages 641-694 of May 20, 1987, issued by Tokyo Chemical Co., Ltd.). For peptide synthesis, conventional methods such as coupling methods using condensing agents, active ester methods (phenyl esters such as p-nitrophenyl ester (ONp) and pentafluorophenyl ester (Opfp), N-hydroxysuccinimide ester ( N-hydroxydicarboxylic acid imide ester such as ONSu), 1-hydroxybenzotriazole ester (Obt), etc.), mixed acid anhydride method, azide method and the like can be used. In a preferred method, at least a condensing agent (preferably a condensing agent described later, particularly a combination of a condensing agent and a condensing aid described later) is often used.
さらに、ペプチドの合成では、アミノ酸又はペプチドフラグメントの種類に応じて、アミノ基、カルボキシル基、他の官能基(グアニジノ基、イミダゾリル基、メルカプト基、ヒドロキシル基、ω−カルボキシル基など)の保護基による保護と、接触還元や強酸処理(無水フッ化水素、トリフルオロメタンスルホン酸、トリフルオロ酢酸など)による保護基の脱離・除去とが繰り返し行われる。例えば、アミノ基の保護基には、ベンジルオキシカルボニル基(Z)、p−メトキシベンジルオキシカルボニル基(Z(OMe))、9−フルオレニルメトキシカルボニル基(Fmoc)、t−ブトキシカルボニル基(Boc)、3−ニトロ−2−ピリジンスルフェニル基(Npys)などが利用でき、カルボキシル基の保護基には、ベンジルオキシ基(OBzl),フェナシルオキシ基(OPac)、t−ブトキシ基(OBu)、メトキシ基(OMe)、エトキシ基(OEt)などが利用できる。なお、ペプチド合成には自動合成装置を利用してもよい。 Furthermore, in peptide synthesis, depending on the type of amino acid or peptide fragment, depending on the type of amino group, carboxyl group, or other functional group (guanidino group, imidazolyl group, mercapto group, hydroxyl group, ω-carboxyl group, etc.) Protection and elimination / removal of the protective group by catalytic reduction or strong acid treatment (anhydrous hydrogen fluoride, trifluoromethanesulfonic acid, trifluoroacetic acid, etc.) are repeated. For example, amino-protecting groups include benzyloxycarbonyl group (Z), p-methoxybenzyloxycarbonyl group (Z (OMe)), 9-fluorenylmethoxycarbonyl group (Fmoc), t-butoxycarbonyl group ( Boc), 3-nitro-2-pyridinesulfenyl group (Npys) and the like, and the protective group for the carboxyl group includes benzyloxy group (OBzl), phenacyloxy group (OPac), t-butoxy group (OBu ), Methoxy group (OMe), ethoxy group (OEt), and the like. An automatic synthesizer may be used for peptide synthesis.
より具体的には、前記ペプチド鎖の固相合成法による調製は、慣用の方法で行うことができる。固相樹脂(又は担体)としては、反応溶媒に不溶性の重合体、例えば、スチレン−ジビニルベンゼン共重合体、例えば、クロロメチル化樹脂、ヒドロキシメチル樹脂、ヒドロキシメチルフェニルアセトアミドメチル樹脂、4−メチルベンズヒドリルアミン樹脂などが利用できる。 More specifically, the peptide chain can be prepared by a solid phase synthesis method by a conventional method. As the solid phase resin (or carrier), a polymer insoluble in the reaction solvent, for example, styrene-divinylbenzene copolymer, for example, chloromethylated resin, hydroxymethyl resin, hydroxymethylphenylacetamidomethyl resin, 4-methylbenz A hydrylamine resin can be used.
固相合成法では、通常、(i)前記重合体(樹脂)に対して、目的とするペプチドのC末端からN末端の方向に向かって、遊離のα−COOH基を有するとともに官能基(少なくともN末端のα−アミノ基など)が保護基で保護されたアミノ酸又はペプチド断片を結合させる操作と、(ii)結合したアミノ酸又はペプチド断片のうちペプチド結合を形成するα−アミノ基の保護基を除去する操作と、(iii)上記結合操作と除去操作とを順次繰り返すことにより、ペプチド鎖を伸長させて目的ペプチドに対応するペプチド鎖を形成する工程と、(iv)ペプチド鎖を重合体(樹脂)から脱離させ、かつ保護されている官能基から保護基を除去することにより、目的とするペプチドを生成させ、生成したペプチドを精製することにより、ペプチドを製造できる。前記アミノ酸又はペプチド断片を結合させる操作(i)では、前記ペプチド鎖のC末端に対応し、かつ遊離のα−COOH基を有するとともに少なくともN末端が保護基で保護されたアミノ酸(例えば、Fmoc−アミノ酸、Boc−アミノ酸など)が使用される。なお、ペプチド鎖の重合体からの脱離及び保護基の除去は、トリフルオロ酢酸を用いて同時に行うのが副反応を抑制する観点から好ましい。また、生成したペプチドの精製は、逆相液体クロマトグラフィーやゲルパーミエイションクロマトグラフィーなどの分離精製手段を利用して行うことができる。 In the solid-phase synthesis method, usually (i) the polymer (resin) has a free α-COOH group and a functional group (at least at the C-terminal to N-terminal direction of the target peptide). (Ii) an α-amino group protecting group that forms a peptide bond among the bound amino acids or peptide fragments; (Iii) a step of extending the peptide chain to form a peptide chain corresponding to the target peptide by sequentially repeating the above binding operation and the removing operation; and (iv) a peptide chain that is a polymer (resin ) And removing the protecting group from the protected functional group to produce the desired peptide, and purify the produced peptide to produce the peptide. In the operation (i) for binding the amino acid or peptide fragment, an amino acid corresponding to the C-terminus of the peptide chain and having a free α-COOH group and at least the N-terminus protected with a protecting group (for example, Fmoc- Amino acids, Boc-amino acids, etc.) are used. The elimination of the peptide chain from the polymer and the removal of the protecting group are preferably performed simultaneously using trifluoroacetic acid from the viewpoint of suppressing side reactions. Further, the produced peptide can be purified using a separation and purification means such as reverse phase liquid chromatography or gel permeation chromatography.
ポリペプチド(I)は、例えば、少なくとも下記式(1a)で表されるペプチド又はその誘導体(A)を縮合し、ポリペプチドを調製する。 Polypeptide (I) is prepared by, for example, condensing at least a peptide represented by the following formula (1a) or a derivative (A) thereof.
X-(Pro-Y-Gly)n-OH (1a)
(式中、XはH又はHOOC-(CH2)m-CO-(mは前記に同じ)を表し、Y及びnは前記に同じ)。
X- (Pro-Y-Gly) n -OH (1a)
(Wherein X represents H or HOOC— (CH 2 ) m —CO— (m is the same as above), and Y and n are the same as above).
前記式(1a)で表されるペプチド又はその誘導体(A)は、下記式(2a)で示されるペプチド又はその誘導体(B)と共縮合させて、ポリペプチドを調製してもよい。 The peptide represented by the formula (1a) or its derivative (A) may be co-condensed with the peptide represented by the following formula (2a) or its derivative (B) to prepare a polypeptide.
X-(Z)r-OH (2a)
(式中、XはH又はHOOC-(CH2)m-CO-(mは前記に同じ)を表し、Z及びrは前記に同じ)。
X- (Z) r -OH (2a)
(Wherein X represents H or HOOC— (CH 2 ) m —CO— (m is the same as above), and Z and r are the same as above).
なお、前記X=HOOC-(CH2)m-CO-に対応する化合物としては、例えば、マロン酸、コハク酸、グルタル酸、アジピン酸、ピメリン酸、スベリン酸、アゼライン酸、セバシン酸などのC3-20の脂肪族ジカルボン酸又はそれらの酸無水物などが例示できる。これらの化合物は、単独で又は二種以上組み合わせて使用できる。これらの化合物も慣用のアミド結合生成法(例えば、後述する第三級アミンなどを触媒とする反応など)反応や前記ペプチド合成法に従って反応させることにより、前記(1a)及び(2a)で示される化合物を得ることができる。 Examples of the compound corresponding to X = HOOC— (CH 2 ) m —CO— include, for example, C such as malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, and sebacic acid. Examples thereof include 3-20 aliphatic dicarboxylic acids or acid anhydrides thereof. These compounds can be used alone or in combination of two or more. These compounds are also represented by the above (1a) and (2a) by reacting according to a conventional amide bond formation method (for example, a reaction using a tertiary amine or the like described later as a catalyst) reaction or the peptide synthesis method. A compound can be obtained.
ペプチド又はその誘導体(A)とペプチド又その誘導体(B)との使用割合は、例えば、前者(A)/後者(B)=100/0〜30/70(モル%)、好ましくは100/0〜40/60(モル%)、さらに好ましくは100/0〜50/50(モル%)程度である。 The ratio of the peptide or its derivative (A) to the peptide or its derivative (B) is, for example, the former (A) / the latter (B) = 100/0 to 30/70 (mol%), preferably 100/0. It is about -40/60 (mol%), More preferably, it is about 100 / 0-50 / 50 (mol%).
さらに、前記式(1a)及び/又は式(2a)においてXがHである場合には必要ではないが、XがHOOC-(CH2)m-CO-(mは前記に同じ)であるとき、前記ペプチド又はその誘導体(A)及び/又はペプチド又はその誘導体(B)は、アミド基を形成するため、下記式(3a)で表される化合物(C)との共縮合反応に供される。 Further, it is not necessary when X is H in the formula (1a) and / or the formula (2a), but when X is HOOC— (CH 2 ) m —CO— (m is the same as above). The peptide or its derivative (A) and / or the peptide or its derivative (B) is subjected to a cocondensation reaction with the compound (C) represented by the following formula (3a) in order to form an amide group. .
H2N-R-NH2 (3a)
(式中、Rは前記に同じ)。
H 2 NR-NH 2 (3a)
(Wherein R is the same as above).
前記式(3a)で表される化合物としては、前記式(3)に対応するジアミン類、例えば、エチレンジアミン、トリメチレンジアミン、プロピレンジアミン、テトラメチレンジアミン、ヘキサメチレンジアミンなどのC1-18アルキレンジアミン、ジエチレントリアミン、ヘキサメチレンテトラミンなどのポリアルキレンポリアミン類などが例示できる。これらの化合物は、単独で又は二種以上組み合わせて使用できる。 Examples of the compound represented by the formula (3a) include diamines corresponding to the formula (3), for example, C 1-18 alkylenediamine such as ethylenediamine, trimethylenediamine, propylenediamine, tetramethylenediamine, and hexamethylenediamine. And polyalkylene polyamines such as diethylenetriamine and hexamethylenetetramine. These compounds can be used alone or in combination of two or more.
前記ジアミン化合物(C)の使用量は、例えば、前記ペプチド又はその誘導体(A)(B)のうち一方のペプチド又はその誘導体がX=HOOC-(CH2)m-CO-(mは前記に同じ)を有する場合、このような基を有するペプチド又はその誘導体1モルに対して、前記ジアミン化合物(C)の使用量は、実質的に1モル(例えば、0.95〜1.05モル程度)用いる必要がある。 The amount of the diamine compound (C) used is, for example, that X = HOOC— (CH 2 ) m —CO— (where m is In the case of having the same), the amount of the diamine compound (C) used is substantially 1 mol (for example, about 0.95 to 1.05 mol) with respect to 1 mol of the peptide or derivative thereof having such a group. ) It is necessary to use.
ポリペプチド(II)の調製において、前記アミノ酸配列を有するペプチドを少なくとも含むペプチド成分を反応させる方法には、(a)式(4)及び(5)で表される双方のアミノ酸配列を有するペプチド(すなわち、式(4)で表されるアミノ酸配列を有するペプチドユニットと、式(5)で表されるアミノ酸配列を有するペプチドユニットとの双方のユニットを有するペプチド)を少なくとも含むペプチド成分を縮合する方法と、(b)式(4)で表されるアミノ酸配列を有するペプチドと、式(5)で表されるアミノ酸配列を有するペプチドとを少なくとも含むペプチド成分を縮合する方法とが含まれる。 In the preparation of polypeptide (II), a method of reacting a peptide component containing at least a peptide having the amino acid sequence includes (a) a peptide having both amino acid sequences represented by formulas (4) and (5) ( That is, a method of condensing a peptide component containing at least a peptide unit having a peptide unit having an amino acid sequence represented by formula (4) and a peptide unit having an amino acid sequence represented by formula (5)) And (b) a method of condensing a peptide component comprising at least a peptide having an amino acid sequence represented by formula (4) and a peptide having an amino acid sequence represented by formula (5).
前者の方法(a)において、式(1)及び(2)で表される双方のアミノ酸配列を有するペプチドは、単独で又は二種以上組み合わせて使用できる。また、この方法において、ペプチド成分としては、前記ペプチドに加え、目的のポリペプチドに応じて他のペプチドを用いてもよい。他のペプチドとしては、例えば、式(1)で表されるアミノ酸配列を有するペプチド、式(2)で表されるアミノ酸配列を有するペプチドの他、前述の他のアミノ酸残基やペプチド鎖を含むペプチドなどが挙げられる。これらの他のペプチドも、単独で又は二種以上組み合わせて使用できる。なお、この方法において、式(1)又は(2)で表されるアミノ酸配列を有するペプチドを共縮合することにより、容易にユニット(1)又は(2)の割合を調整することができる。 In the former method (a), peptides having both amino acid sequences represented by the formulas (1) and (2) can be used alone or in combination of two or more. In this method, as the peptide component, in addition to the peptide, other peptides may be used according to the target polypeptide. Examples of other peptides include the peptide having the amino acid sequence represented by formula (1), the peptide having the amino acid sequence represented by formula (2), and the other amino acid residues and peptide chains described above. Peptide etc. are mentioned. These other peptides can also be used alone or in combination of two or more. In this method, the ratio of units (1) or (2) can be easily adjusted by co-condensing a peptide having the amino acid sequence represented by formula (1) or (2).
後者の方法(b)においても、式(1)で表されるアミノ酸配列を有するペプチド、式(2)で表されるアミノ酸配列を有するペプチドは、それぞれ、単独で又は二種以上組み合わせて使用できる。また、この方法においても、ペプチド成分として、これらのペプチド(1)及び(2)に加え、目的のポリペプチドに応じて他のペプチド、例えば、前述の他のアミノ酸残基やペプチド鎖を含むペプチドなどを用いてもよい。これらの他のペプチドも、単独で又は二種以上組み合わせて使用できる。 Also in the latter method (b), the peptide having the amino acid sequence represented by formula (1) and the peptide having the amino acid sequence represented by formula (2) can be used alone or in combination of two or more. . Also in this method, as a peptide component, in addition to these peptides (1) and (2), other peptides according to the target polypeptide, for example, peptides containing other amino acid residues and peptide chains as described above Etc. may be used. These other peptides can also be used alone or in combination of two or more.
これらのペプチド成分の縮合反応は、通常、溶媒中で行われる。溶媒は、上記ペプチド成分を溶解又は懸濁(一部または全部を溶解)可能であればよく、通常、水及び/又は有機溶剤が使用できる。溶媒としては、例えば、水、アミド類(ジメチルホルムアミド、ジメチルアセトアミド、ヘキサメチルホスホロアミドなど)、スルホキシド類(ジメチルスルホキシドなど)、窒素含有環状化合物(N−メチルピロリドン、ピリジンなど)、ニトリル類(アセトニトリルなど)、エーテル類(ジオキサン、テトラヒドロフランなど)、アルコール類(メチルアルコール、エチルアルコール、プロピルアルコールなど)、及びこれらの混合溶媒が例示できる。これらの溶媒のうち、水、ジメチルホルムアミド、ジメチルスルホキシドが繁用される。 The condensation reaction of these peptide components is usually performed in a solvent. The solvent only needs to be able to dissolve or suspend the peptide component (partially or completely dissolve), and water and / or an organic solvent can be usually used. Examples of the solvent include water, amides (dimethylformamide, dimethylacetamide, hexamethylphosphoramide, etc.), sulfoxides (dimethylsulfoxide, etc.), nitrogen-containing cyclic compounds (N-methylpyrrolidone, pyridine, etc.), nitriles ( Examples include acetonitrile (such as acetonitrile), ethers (such as dioxane and tetrahydrofuran), alcohols (such as methyl alcohol, ethyl alcohol, and propyl alcohol), and mixed solvents thereof. Of these solvents, water, dimethylformamide, and dimethyl sulfoxide are frequently used.
これらのペプチド成分の反応は、通常、少なくとも脱水剤(脱水縮合剤)又は縮合剤の存在下で行うことができ、脱水縮合剤と縮合助剤との存在下で反応させると、二量化や環化を抑制しつつ、円滑にポリペプチドを生成できる。 The reaction of these peptide components can usually be carried out in the presence of at least a dehydrating agent (dehydrating condensing agent) or a condensing agent. A polypeptide can be produced smoothly while suppressing the conversion.
脱水縮合剤は、前記溶媒中で脱水縮合を効率よく行える限り特に制限されず、例えば、カルボジイミド系縮合剤[ジイソプロピルカルボジイミド(DIPC)、1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド(EDC=WSCI)、1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド塩酸塩(WSCI・HCl)、ジシクロヘキシルカルボジイミド(DCC)など]、フルオロホスフェート系縮合剤[O−(7−アザベンゾトリアゾール−1−イル)−1,1,3,3−テトラメチルウロニウムヘキサフルオロホスフェート、O−ベンゾトリアゾール−1−イル−N,N,N′,N′−テトラメチルウロニウムヘキサフルオロホスフェート、ベンゾトリアゾール−1−イル−オキシ−トリス−ピロリジノホスホニウムヘキサフルオロホスフェート、ベンゾトリアゾール−1−イル−トリス(ジメチルアミノ)ホスホニウムヘキサフルオロリン化物塩(BOP)など]、ジフェニルホスホリルアジド(DPPA)などが例示できる。これらの脱水縮合剤は単独で又は二種以上組み合わせて混合物として使用できる。好ましい脱水縮合剤は、カルボジイミド系縮合剤[例えば、1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド、1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド塩酸塩]である。 The dehydrating condensing agent is not particularly limited as long as dehydrating condensation can be efficiently performed in the solvent. For example, a carbodiimide condensing agent [diisopropylcarbodiimide (DIPC), 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimide ( EDC = WSCI), 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimide hydrochloride (WSCI · HCl), dicyclohexylcarbodiimide (DCC), etc.], fluorophosphate condensing agent [O- (7-azabenzotriazole -1-yl) -1,1,3,3-tetramethyluronium hexafluorophosphate, O-benzotriazol-1-yl-N, N, N ′, N′-tetramethyluronium hexafluorophosphate, benzo Triazol-1-yl-oxy-tris-pyrrolidinophosphonium hexafluorophosphate Benzotriazol-1-yl - tris (dimethylamino) phosphonium hexafluorophosphate product salt (BOP)], such as diphenylphosphoryl azide (DPPA) can be exemplified. These dehydration condensing agents can be used alone or in combination of two or more. A preferred dehydrating condensing agent is a carbodiimide condensing agent [for example, 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimide, 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimide hydrochloride].
縮合助剤は、上記縮合剤の反応を促進する限り特に制限されず、例えば、N−ヒドロキシ多価カルボン酸イミド類[例えば、N−ヒドロキシコハク酸イミド(HONSu)、N−ヒドロキシ−5−ノルボルネン−2,3−ジカルボン酸イミド(HONB)などのN−ヒドロキシジカルボン酸イミド類]、N−ヒドロキシトリアゾール類[例えば、1−ヒドロキシベンゾトリアゾール(HOBt)などのN−ヒドロキシベンゾトリアゾール類]、3−ヒドロキシ−4−オキソ−3,4−ジヒドロ−1,2,3−ベンゾトリアジン(HOObt)などのトリアジン類、2−ヒドロキシイミノ−2−シアノ酢酸エチルエステルなどが例示できる。これらの縮合助剤も単独で又は二種以上組み合わせて使用できる。好ましい縮合助剤は、N−ヒドロキシジカルボン酸イミド類[HONSuなど]、N−ヒドロキシベンゾトリアゾール又はN−ヒドロキシベンゾトリアジン類[HOBtなど]である。 The condensation aid is not particularly limited as long as it promotes the reaction of the condensation agent. For example, N-hydroxypolycarboxylic imides [for example, N-hydroxysuccinimide (HONSu), N-hydroxy-5-norbornene N-hydroxydicarboxylic imides such as -2,3-dicarboxylic acid imide (HONB)], N-hydroxytriazoles [for example, N-hydroxybenzotriazoles such as 1-hydroxybenzotriazole (HOBt)], 3- Examples thereof include triazines such as hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine (HOObt), and 2-hydroxyimino-2-cyanoacetic acid ethyl ester. These condensation aids can also be used alone or in combination. Preferred condensation aids are N-hydroxydicarboxylic imides [such as HONSu], N-hydroxybenzotriazole or N-hydroxybenzotriazines [such as HOBt].
前記脱水縮合剤と縮合助剤とは適当に組み合わせて使用できる。前記脱水縮合剤と縮合助剤との組合せとしては、例えば、DCC-HONSu(HOBt又はHOObt)、WSCI-HONSu(HOBt又はHOObt)などが例示できる。 The dehydration condensation agent and the condensation aid can be used in appropriate combination. Examples of the combination of the dehydrating condensing agent and the condensing aid include DCC-HONSu (HOBt or HOObt), WSCI-HONSu (HOBt or HOObt), and the like.
脱水縮合剤の使用量は、前記ペプチド成分(前記ジアミン化合物も含む)の総量1モルに対して、通常、水を含まない非水系溶媒を用いる場合0.7〜5モル、好ましくは0.8〜2.5モル、さらに好ましくは0.9〜2.3モル(例えば1〜2モル)程度である。水を含む溶媒(水系溶媒)においては、水による脱水縮合剤の失活があるので、脱水縮合剤の使用量は、前記ペプチド成分の総量1モルに対して、通常、2〜500モル(例えば、2〜50モル)、好ましくは5〜250モル(例えば、5〜25モル)、さらに好ましくは10〜125モル(例えば、10〜20モル)程度である。縮合助剤の使用量は、溶媒の種類に関係なく、前記ペプチド成分の総量1モルに対して、例えば、0.5〜5モル、好ましくは0.7〜2モル、さらに好ましくは0.8〜1.5モル程度である。 The amount of the dehydrating condensing agent used is usually 0.7 to 5 mol, preferably 0.8 when a non-aqueous solvent not containing water is used per 1 mol of the total amount of the peptide component (including the diamine compound). It is about -2.5 mol, More preferably, it is about 0.9-2.3 mol (for example, 1-2 mol). In a solvent containing water (aqueous solvent), since the dehydration condensation agent is deactivated by water, the amount of the dehydration condensation agent used is usually 2 to 500 mol (for example, relative to 1 mol of the total amount of the peptide components). 2 to 50 mol), preferably 5 to 250 mol (for example, 5 to 25 mol), and more preferably about 10 to 125 mol (for example, 10 to 20 mol). The amount of the condensation aid used is, for example, 0.5 to 5 mol, preferably 0.7 to 2 mol, more preferably 0.8, relative to 1 mol of the total amount of the peptide components regardless of the type of solvent. About 1.5 mol.
前記縮合反応において、反応系のpHを調節してもよく、反応に関与しない塩基を添加してもよい。pHの調節は、通常、無機塩基[水酸化ナトリウム、水酸化カリウム、炭酸ナトリウム、炭酸水素ナトリウムなど]、有機塩基、無機酸[塩酸など]や有機酸を用いて行うことができ、通常、反応溶液が中性付近(pH=6〜8程度)にpH調整される。前記反応に関与しない塩基としては、第三級アミン類、例えば、トリメチルアミン、トリエチルアミン、ジイソプロピルエチルアミンなどのトリアルキルアミン類、N−メチルモルホリン、ピリジンなどの複素環式第三級アミン類などが例示できる。このような塩基の使用量は、通常、ペプチドの総モル数の1〜2倍程度の範囲から選択できる。 In the condensation reaction, the pH of the reaction system may be adjusted, or a base that does not participate in the reaction may be added. The pH can be adjusted usually using an inorganic base [sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogen carbonate, etc.], an organic base, an inorganic acid [hydrochloric acid, etc.] or an organic acid. The pH of the solution is adjusted to near neutral (pH = about 6 to 8). Examples of the base not involved in the reaction include tertiary amines such as trialkylamines such as trimethylamine, triethylamine and diisopropylethylamine, and heterocyclic tertiary amines such as N-methylmorpholine and pyridine. . The amount of such base used can usually be selected from a range of about 1 to 2 times the total number of moles of the peptide.
前記ポリペプチドが3重らせん構造を形成することは、通常、ポリペプチドの溶液について、円二色性スペクトルを測定することにより立証できる。特に、円二色性スペクトルにおいては、3重らせん構造を形成する天然のコラーゲン及びペプチド鎖が、波長220nm〜230nmに正のコットン効果、及び波長195nm〜205nmに負のコットン効果を特徴的に示すことが報告されている(J. M. Biol., Vol.63 pp.85-99, 1972年)。 The formation of a triple helical structure by the polypeptide can usually be verified by measuring a circular dichroism spectrum of the polypeptide solution. In particular, in the circular dichroism spectrum, natural collagen and peptide chains forming a triple helical structure characteristically show a positive cotton effect at wavelengths of 220 nm to 230 nm and a negative cotton effect at wavelengths of 195 nm to 205 nm. (JM Biol., Vol. 63 pp. 85-99, 1972).
このようなポリペプチドは、哺乳動物由来のコラーゲンと異なり、病原体や病原性因子[例えば、病原性に転化したタンパク質(例えば、異常型プリオンなど)など]の感染や伝達の危険性がない。そのため、前記ポリペプチドは、安全性が高い。しかも、高い保湿性及び安定性を有しており、化粧料の成分として有用である。 Unlike a mammal-derived collagen, such a polypeptide has no risk of infection or transmission of pathogens or pathogenic factors [for example, proteins converted to pathogenicity (for example, abnormal prions, etc.)]. Therefore, the polypeptide is highly safe. Moreover, it has high moisture retention and stability and is useful as a cosmetic ingredient.
[化粧料]
本発明の化粧料は、少なくとも前記ポリペプチドを含んでいればよく、粉末状基剤を含む粉末状化粧料、固形又は半固形状基剤(水性基剤、ゲル基剤、又は油性基剤)を含む固形又は半固形状化粧料、液状基剤(水性又は油性基剤)を含む液状化粧料のいずれであってもよい。また、化粧料は、通常、基剤(又は担体)と有効成分(保湿剤など)と添加剤とを含んでおり、前記ポリペプチドは、これらの成分のうち少なくとも1つの成分として含有されていればよい。
[Cosmetics]
The cosmetic of the present invention is only required to contain at least the polypeptide, and is a powdery cosmetic including a powdery base, a solid or semi-solid base (aqueous base, gel base, or oily base). Any of a solid or semi-solid cosmetic containing a liquid and a liquid cosmetic containing a liquid base (aqueous or oily base) may be used. In addition, cosmetics usually contain a base (or carrier), an active ingredient (such as a humectant), and an additive, and the polypeptide may be contained as at least one of these ingredients. That's fine.
ポリペプチドの含有量は、化粧料の種類や剤形などに応じて広い範囲、例えば、0.001〜99重量%程度の範囲から選択できる。ポリペプチドを基剤として用いる場合、ポリペプチドの割合は、化粧料全体に対して、例えば10〜99重量%、好ましくは20〜99重量%、さらに好ましくは30〜95重量%程度であってもよい。有効成分として用いる場合、前記割合は、例えば0.001〜95重量%、好ましくは0.01〜90重量%、さらに好ましくは0.1〜90重量%程度であってもよい。また、添加剤として用いる場合、前記割合は0.001〜40重量%、好ましくは0.01〜30重量%、さらに好ましくは0.1〜20重量%程度であってもよい。 The content of the polypeptide can be selected from a wide range, for example, a range of about 0.001 to 99% by weight, depending on the type and dosage form of the cosmetic. When the polypeptide is used as a base, the ratio of the polypeptide is, for example, 10 to 99% by weight, preferably 20 to 99% by weight, more preferably about 30 to 95% by weight, based on the entire cosmetic. Good. When used as an active ingredient, the ratio may be, for example, about 0.001 to 95% by weight, preferably about 0.01 to 90% by weight, and more preferably about 0.1 to 90% by weight. Moreover, when using as an additive, the said ratio may be 0.001 to 40 weight%, Preferably it is 0.01 to 30 weight%, More preferably, about 0.1 to 20 weight% may be sufficient.
ポリペプチドは、他の基剤と組み合わせてもよい。基剤のうち粉末状基剤としては、糖類(グルコース、ラクトース、デンプンなどの単糖類又は多糖類;ソルビトールなどの糖アルコールなど)、アミノ酸類(セリン、グリシン、スレオニン、アラニンなど)、金属石鹸類(脂肪酸金属塩、例えば、ステアリン酸カリウム、やし油脂肪酸ナトリウム、ミリスチン酸マグネシウム、ステアリン酸カルシウムなど)、樹脂類[ポリエチレンなどのオレフィン系樹脂、スチレン系樹脂、アクリル系樹脂、ビニルアルコール系重合体、カルボン酸ビニルエステル系樹脂、ポリアミド系樹脂、ポリエステル系樹脂などの熱可塑性樹脂;フェノール樹脂、アミン樹脂(尿素樹脂、メラミン樹脂など)、熱硬化性アクリル樹脂、不飽和ポリエステル樹脂、アルキド樹脂、エポキシ樹脂、シリコーン樹脂(メチルポリシロキサンなど)などの熱硬化性樹脂など]、無機粉末成分[セリサイト、体質顔料(カオリン、タルク、雲母などの天然粘度鉱物;合成フッ素金雲母、六方晶窒化ホウ素など)など]などが挙げられる。 The polypeptide may be combined with other bases. Among the bases, powdery bases include saccharides (monosaccharides or polysaccharides such as glucose, lactose, starch; sugar alcohols such as sorbitol), amino acids (serine, glycine, threonine, alanine, etc.), metal soaps (Fatty acid metal salts such as potassium stearate, sodium palm fatty acid fatty acid, magnesium myristate, calcium stearate), resins [olefin resins such as polyethylene, styrene resins, acrylic resins, vinyl alcohol polymers, Thermoplastic resins such as carboxylic acid vinyl ester resin, polyamide resin, and polyester resin; phenol resin, amine resin (urea resin, melamine resin, etc.), thermosetting acrylic resin, unsaturated polyester resin, alkyd resin, epoxy resin , Silicone resin Thermosetting resins such as polysiloxane], inorganic powder components [sericite, extender pigments (natural viscosity minerals such as kaolin, talc, mica; synthetic fluorine phlogopite, hexagonal boron nitride, etc.)], etc. It is done.
固形又は半固形基剤としては、動植物由来の固形又は半固形油性基剤(蜜ろう、木ろう、カルナバろう、キャンデリラろう、カカオ脂、牛脂;ラノリンなど)、鉱物由来の固形又は半固形油性基剤(固形パラフィン、セレシン、ミクロクリスタリンワックス;ワセリンなど)の他、脂肪酸エステル(2−エチルヘキサン酸セチルなどの飽和又は不飽和脂肪酸アルキルエステル;リンゴ酸イソステアリルなどの飽和又は不飽和オキシ酸アルキルエステル;グリセリルモノステアレート、エチレングリコールジステアリン酸エステルなどの飽和脂肪酸と多価アルコールとのエステルなど)、高級アルコール(セチルアルコール、ステアリルアルコール、オレイルアルコールなどの飽和脂肪族アルコールなど)、高級脂肪酸(ステアリン酸、オレイン酸など)、ゲル基剤(粘液質など)などが挙げられる。前記ゲル基剤の粘液質としては、動植物系粘液質(クインシードガム、トラガントガム、キサンタンガムなどのガム類;ペクチン、デンプンなどの糖類;アイリッシュモス;アルギン酸ナトリウム、プロピレングリコールアルギネートなどのアルギン酸類;ヒアルロン酸、コンドロイチン硫酸ナトリウム、コンドロイチンヘパリンなどの多糖類;カゼイン、ビトロネクチン、フィブロネクチン、ケラチン、エラスチン、ローヤルゼリーなどのタンパク質類など)、セルロース又はその誘導体(セルロース;メチルセルロース、エチルセルロース、カルボキシメチルセルロース、ヒドロキシエチルセルロースなど)、合成ポリマー(ポリアクリル酸ナトリウム、ポリビニルアルコール、ポリビニルメチルエーテル、ポリビニルピロリドン、カルボキシビニルポリマー、高分子量のポリオキシアルキレングリコール(ポリエチレングリコールなど)など)、無機系粘液質(ビーガム、ベントナイト、有機変性ベントナイト、膨潤性ベントナイトなど)などが挙げられる。 Solid or semi-solid bases include animal or plant-derived solid or semi-solid oily bases (honey wax, wood wax, carnauba wax, candelilla wax, cacao butter, beef tallow; lanolin, etc.), mineral-derived solid or semi-solid oil bases In addition to agents (solid paraffin, ceresin, microcrystalline wax; petrolatum, etc.), fatty acid esters (saturated or unsaturated fatty acid alkyl esters such as cetyl 2-ethylhexanoate; saturated or unsaturated oxyacid alkyl esters such as isostearyl malate) Glyceryl monostearate, esters of saturated fatty acids such as ethylene glycol distearate and polyhydric alcohols), higher alcohols (such as saturated aliphatic alcohols such as cetyl alcohol, stearyl alcohol, oleyl alcohol), higher fatty acids (stearic acid) Olei Acid, etc.), gel base (such as mucus) and the like. Examples of the mucus of the gel base include animal and plant mucus (gum such as quinseed gum, tragacanth gum and xanthan gum; sugars such as pectin and starch; Irish moss; alginic acids such as sodium alginate and propylene glycol alginate; hyaluronic acid, Polysaccharides such as sodium chondroitin sulfate and chondroitin heparin; proteins such as casein, vitronectin, fibronectin, keratin, elastin, royal jelly, etc., cellulose or derivatives thereof (cellulose; methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxyethylcellulose, etc.), synthetic polymers (Sodium polyacrylate, polyvinyl alcohol, polyvinyl methyl ether, polyvinyl pyrrolidone, cal Carboxyvinyl polymers, such as high molecular weight polyoxyalkylene glycols (such as polyethylene glycol)), inorganic mucous (Veegum, bentonite, organic modified bentonite, such swellable bentonite) and the like.
液状基剤としては、油性基剤(ホホバ油、オリーブ油、やし油、つばき油、マカデミアンナッツ油、ひまし油、スクアランなど)、鉱物系油性基剤(流動パラフィン、ポリブテン、シリコーン油など)、合成系油性基剤(合成エステル油、合成ポリエーテル油など)などの油性基剤;水性基剤、例えば、水、水溶性有機溶媒[低級脂肪族アルコール(エタノール、イソプロパノールなど);アルキレングリコール類(エチレングリコール、ジエチレングリコール、プロピレングリコール、ジプロピレングリコール、1,3−ブチレングリコール、ポリエチレングリコール、ジエチレングリコールモノエチルエステルなどの低分子量のポリオキシアルキレングリコール又はそのモノアルキルエステルなど);グリセリン、ペンタエリスリトールなどの多価アルコール類;乳酸、ピロリドンカルボン酸ナトリウムなどのカルボン酸類]などが挙げられる。基剤は、単独で又は二種以上組み合わせて使用できる。 Liquid bases include oil bases (jojoba oil, olive oil, palm oil, camellia oil, macadamia nut oil, castor oil, squalane, etc.), mineral oil bases (liquid paraffin, polybutene, silicone oil, etc.), synthetic Oily bases such as oil-based bases (synthetic ester oils, synthetic polyether oils, etc.); aqueous bases such as water, water-soluble organic solvents [lower aliphatic alcohols (ethanol, isopropanol, etc.); alkylene glycols (ethylene Glycol, diethylene glycol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, polyethylene glycol, diethylene glycol monoethyl ester and other low molecular weight polyoxyalkylene glycols or monoalkyl esters thereof); glycerin, pentaerythritol What polyhydric alcohols; lactic, carboxylic acids such as sodium pyrrolidone carboxylic acid] and the like. A base can be used individually or in combination of 2 or more types.
基剤の割合は、化粧品全体に対して、10〜99.999重量%、好ましくは10〜99重量%、さらに好ましくは20〜95重量%程度であってもよい。また、ポリペプチドの割合は、基剤100重量部に対して、0.001〜500重量部、好ましくは0.01〜300重量部、さらに好ましくは0.1〜100重量部(例えば、1〜50重量部)程度であってもよい。 The ratio of the base may be about 10 to 99.999% by weight, preferably 10 to 99% by weight, and more preferably about 20 to 95% by weight with respect to the entire cosmetic. Moreover, the ratio of polypeptide is 0.001-500 weight part with respect to 100 weight part of bases, Preferably it is 0.01-300 weight part, More preferably, it is 0.1-100 weight part (for example, 1-100 weight part). 50 parts by weight).
ポリペプチドは、他の有効成分と組み合わせてもよい。有効成分としては、収れん剤(クエン酸、乳酸、酒石酸などのオキシ酸又はこれらの塩など;塩化アルミニウムなどのアルミニウム化合物;硫酸亜鉛、スルホフェノキソ亜鉛などの亜鉛化合物;プロアントシアニジン類;ハマメリス、白樺などのタンニン含有植物抽出物;ガイヨウエキス、ダイオウエキス、スギナエキスなど)、エモリエント剤(トリグリセリド油、スクワラン、エステル油などの油性成分を、モノグリセリドなどの非イオン乳化剤などにより乳化した乳化物など)、保湿剤、皮膚軟化剤(サリチル酸又はその誘導体、乳酸、尿素など)、抗酸化剤(トコフェロール又はその誘導体;アントシアニンなどのポリフェノール類など)、紫外線吸収剤や紫外線を散乱する無機顔料、美白剤(アスコルビン酸又はその誘導体、システイン、プラセンタエキス、アルブチン、コウジ酸、ルシノール、エラグ酸、カミツレ抽出物など)、制汗剤(アルミニウム化合物、亜鉛化合物、タンニンなどの収れん剤など)、肌荒れ防止剤(グリチルリチン酸塩、ビタミン類など)、抗炎症剤(アラントイン、グアイアズレン、グリチルリチン酸又はその塩、グリチルレチン酸又はその塩、ε−アミノカプロン酸、トラネキサム酸、イブプロフェン、インドメタシン、酸化亜鉛、或いはこれらの誘導体;アルニカ抽出物などの植物抽出物など)、殺菌剤又は抗菌剤(塩化ベンザルコニウム、塩化ジステアリルメチルアンモニウムなどの第四級アンモニウム塩;安息香酸、安息香酸ナトリウム、パラオキシ安息香酸エステルなどの安息香酸類;サリチル酸、サリチル酸ナトリウムなどのサリチル酸類;トリクロロカルバニリド、トリクロサンなど)、酵素(プロテアーゼ、リパーゼなど)、ビタミン類(ビタミンA、ビタミンB、ビタミンC、ビタミンD、ビタミンE、ビタミンKなど)、アミノ酸(トリプトファン、システインなど)、細胞賦活剤(リボフラビン、ピリドキシン、ニコチン酸、パントテン酸、α−トコフェロール、又はこれらの誘導体;ユキノシタエキスなどの植物抽出物など)などが挙げられる。 The polypeptide may be combined with other active ingredients. Active ingredients include astringents (oxyacids such as citric acid, lactic acid, tartaric acid, and salts thereof; aluminum compounds such as aluminum chloride; zinc compounds such as zinc sulfate and sulfophenoxozinc; proanthocyanidins; Tannin-containing plant extracts such as oyster extract, dio extract, horsetail extract, etc.), emollients (emulsions obtained by emulsifying oil components such as triglyceride oil, squalane, ester oil etc. with nonionic emulsifier such as monoglyceride), moisturizing Agents, emollients (salicylic acid or derivatives thereof, lactic acid, urea, etc.), antioxidants (tocopherol or derivatives thereof; polyphenols such as anthocyanins), UV absorbers, inorganic pigments that scatter UV rays, whitening agents (ascorbic acid) Or a derivative thereof, cis In, placenta extract, arbutin, kojic acid, lucinol, ellagic acid, chamomile extract, etc., antiperspirants (astringents such as aluminum compounds, zinc compounds, tannins), rough skin prevention agents (glycyrrhizinate, vitamins, etc.) ), Anti-inflammatory agents (allantoin, guaiazulene, glycyrrhizic acid or salts thereof, glycyrrhetinic acid or salts thereof, ε-aminocaproic acid, tranexamic acid, ibuprofen, indomethacin, zinc oxide, or derivatives thereof; plant extracts such as Arnica extract ), Bactericides or antibacterial agents (quaternary ammonium salts such as benzalkonium chloride and distearylmethylammonium chloride; benzoic acids such as benzoic acid, sodium benzoate, and paraoxybenzoic acid esters; salicylates such as salicylic acid and sodium salicylate; Tyric acids; trichlorocarbanilide, triclosan, etc., enzymes (proteases, lipases, etc.), vitamins (vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K, etc.), amino acids (tryptophan, cysteine, etc.) And cell activators (riboflavin, pyridoxine, nicotinic acid, pantothenic acid, α-tocopherol, or derivatives thereof; plant extracts such as Yukinosita extract).
前記保湿剤としては、アルキレングリコール類(エチレングリコール、ジエチレングリコール、プロピレングリコール、ジプロピレングリコール、1,3−ブチレングリコール、ポリエチレングリコール、ジエチレングリコールモノエチルエステルなどのポリアルキレングリコール又はそのモノアルキルエステルなど)、グリセリン、ペンタエリスリトールなどの多価アルコール類;乳酸、ピロリドンカルボン酸ナトリウム;アミノ酸類(セリン、グリシン、スレオニン、アラニンなど);糖類(ソルビトールなどの糖アルコール;ヒアルロン酸、コンドロイチン硫酸ナトリウム、コンドロイチンヘパリンなどの多糖類など);タンパク質(ビトロネクチン、フィブロネクチン、ケラチン、エラスチン、ローヤルゼリーなど)などが挙げられる。 Examples of the humectant include alkylene glycols (ethylene glycol, diethylene glycol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, polyethylene glycol, polyalkylene glycol such as diethylene glycol monoethyl ester, and monoalkyl esters thereof), glycerin, and the like. And polyhydric alcohols such as pentaerythritol; lactic acid, sodium pyrrolidone carboxylate; amino acids (serine, glycine, threonine, alanine, etc.); sugars (sugar alcohols such as sorbitol; hyaluronic acid, sodium chondroitin sulfate, chondroitin heparin, etc. Saccharides; proteins (vitronectin, fibronectin, keratin, elastin, royal jelly, etc.) .
前記紫外線吸収剤としては、オキシベンゾン、オキシベンゾンスルホン酸、ヒドロキシメトキシベンゾフェノンスルホン酸ナトリウムなどのベンゾフェノン系吸収剤;メトキシケイ皮酸オクチル、ジイソプロピルケイ皮酸メチル、ジイソプロピルケイ皮酸エチル、p−メトキシケイ皮酸イソプロピル、ジ−p−メトキシケイ皮酸モノ−2−エチルヘキサン酸グリセリルなどのケイ皮酸系吸収剤;p−アミノ安息香酸、p−アミノ安息香酸エチル、p−アミノ安息香酸オクチル、p−ジメチルアミノ安息香酸オクチルなどのp−アミノ安息香酸系吸収剤;サリチル酸オクチルなどのサリチル酸系吸収剤;4−t−ブチル−4’−メトキシベンゾイルメタンなどのジベンゾイルメタン系吸収剤;ウロカニン酸又はそのエステル;β−イソプロピルフラノン;β−カロチンなどが挙げられる。前記紫外線を散乱する無機顔料としては、酸化チタン(二酸化チタン)、酸化ジルコニウム、酸化亜鉛、酸化鉄などが挙げられる。また、有効成分には、用途に応じて、毛髪用化粧料の有効成分(コンディショニング剤、ふけ抑制剤など)、しみそばかす用化粧料の有効成分(チロシナーゼ活性阻害剤、メラニン還元剤など)、ニキビ用化粧料の有効成分(硫黄などの角質軟化剤、消炎剤、副腎皮質ホルモン、皮脂分泌抑制剤など)なども含まれる。前記有効成分は単独で又は二種以上組み合わせて使用できる。 Examples of the ultraviolet absorber include benzophenone-based absorbers such as oxybenzone, oxybenzonesulfonic acid, sodium hydroxymethoxybenzophenone sulfonate; octyl methoxycinnamate, methyl diisopropylcinnamate, ethyl diisopropylcinnamate, p-methoxycinnamate Cinnamic acid-based absorbents such as isopropyl, di-p-methoxycinnamate mono-2-ethylhexanoate glyceryl; p-aminobenzoic acid, ethyl p-aminobenzoate, octyl p-aminobenzoate, p-dimethyl P-aminobenzoic acid absorbents such as octyl aminobenzoate; salicylic acid absorbents such as octyl salicylate; dibenzoylmethane absorbents such as 4-t-butyl-4'-methoxybenzoylmethane; urocanic acid or its ester ; Β-isopropyl Ranong; and β- carotene and the like. Examples of the inorganic pigment that scatters ultraviolet rays include titanium oxide (titanium dioxide), zirconium oxide, zinc oxide, and iron oxide. The active ingredients include hair cosmetic active ingredients (conditioning agents, anti-dandruff agents, etc.), freckles freckles cosmetic active ingredients (tyrosinase activity inhibitors, melanin reducing agents, etc.), acne, etc. Active ingredients of cosmetics for skin use (such as keratin softeners such as sulfur, anti-inflammatory agents, corticosteroids, sebum secretion inhibitors, etc.) are also included. The active ingredients can be used alone or in combination of two or more.
有効成分の割合は、化粧料全体に対して、0.001〜90重量%、好ましくは0.01〜80重量%、さらに好ましくは0.1〜60重量%程度であってもよい。なお、ポリペプチドを保湿剤として用いる場合、他の保湿剤(前記例示の保湿剤)に対する割合(重量比)は、ポリペプチド/他の保湿剤=0.1/99.9〜100/0、好ましくは1/99〜90/10、さらに好ましくは5/95〜80/20程度であってもよい。 The proportion of the active ingredient may be about 0.001 to 90% by weight, preferably 0.01 to 80% by weight, and more preferably about 0.1 to 60% by weight with respect to the entire cosmetic. In addition, when using a polypeptide as a humectant, the ratio (weight ratio) to the other humectant (the humectant illustrated above) is polypeptide / other humectant = 0.1 / 99.9 to 100/0, Preferably it may be about 1/99 to 90/10, more preferably about 5/95 to 80/20.
ポリペプチドは、他の添加剤と併用してもよい。添加剤としては、界面活性剤、無機塩類(硫酸ナトリウム、炭酸水素ナトリウム、塩化カリウムなど)、着色剤、繊維(ナイロン繊維などの合成繊維、天然繊維など)、研磨剤(リン酸水素カルシウム、炭酸カルシウム、無水ケイ酸など)、発泡剤(ラウリル硫酸ナトリウムなど)、湿潤剤(ソルビット、グリセリンなど)、粘結剤(前記例示の粘液質、例えば、カルボキシルメチルセルロース、カルボキシメチルセルロースナトリウム、カラギーナンなど)、不透明化剤、香料(合成香料、精油、精油成分など)、甘味剤(サッカリンナトリウムなど)、植物抽出物などが挙げられる。 The polypeptide may be used in combination with other additives. Additives include surfactants, inorganic salts (sodium sulfate, sodium bicarbonate, potassium chloride, etc.), colorants, fibers (synthetic fibers such as nylon fibers, natural fibers, etc.), abrasives (calcium hydrogen phosphate, carbonates) Calcium, silicic anhydride, etc., foaming agent (sodium lauryl sulfate, etc.), wetting agent (sorbite, glycerin, etc.), binder (the mucous substances exemplified above, such as carboxymethylcellulose, sodium carboxymethylcellulose, carrageenan, etc.) Agents, fragrances (synthetic fragrances, essential oils, essential oil components, etc.), sweeteners (such as sodium saccharin), plant extracts and the like.
前記界面活性剤としては、陰イオン性界面活性剤(アルキル硫酸塩;アルキルエーテル硫酸ナトリウム、アルキルエーテル硫酸トリエタノールアミンなどのアルキルエーテル硫酸塩;アシルメチルタウリン塩;アシルグルタミン酸ナトリウムなどのアシルグルタミン酸塩;アミドエーテル硫酸塩;ソルビタンセスキオレイン酸エステルなどのソルビタン脂肪酸エステル類;グリセリルモノステアレートなどのグリセリン脂肪酸エステル類;ポリオキシエチレングリセリルモノステアレートなどのポリオキシエチレングリセリン脂肪酸エステルなど)、両性界面活性剤(アルキル酢酸ベタイン、アミド酢酸ベタイン、イミダゾリニウムベタイン(アミンオキシド型半極性界面活性剤)など)、非イオン性界面活性剤(ラウリン酸ジエタノールアミド、ヤシ脂肪酸ジエタノールアミドなどの脂肪酸アルカノールアミド;ポリオキシエチレンオレイルエーテル、ポリオキシエチレンオクチルドデシルエーテルなどのポリオキシエチレンアルキルエーテル;ポリオキシエチレン−ポリオキシプロピレンブロック共重合体;ポリオキシエチレン硬化ひまし油エステルなど)、陽イオン界面活性剤(塩化アルキルトリメチルアンモニウム塩、塩化ジアルキルジメチルアンモニウム塩など)などが挙げられる。 Examples of the surfactant include anionic surfactants (alkyl sulfates; alkyl ether sulfates such as sodium alkyl ether sulfate and alkyl ether sulfate triethanolamine; acylmethyl taurate salts; acyl glutamates such as sodium acyl glutamate; Amide ether sulfates; sorbitan fatty acid esters such as sorbitan sesquioleate; glycerin fatty acid esters such as glyceryl monostearate; polyoxyethylene glycerin fatty acid esters such as polyoxyethylene glyceryl monostearate), amphoteric surfactants (Alkyl acetate betaine, amide acetate betaine, imidazolinium betaine (amine oxide type semipolar surfactant), etc.), nonionic surfactant (lauric acid diethanolate) Fatty acid alkanolamides such as palm fatty acid diethanolamide; polyoxyethylene alkyl ethers such as polyoxyethylene oleyl ether and polyoxyethylene octyldodecyl ether; polyoxyethylene-polyoxypropylene block copolymers; polyoxyethylene hydrogenated castor oil ester And the like, and cationic surfactants (such as alkyltrimethylammonium chloride and dialkyldimethylammonium chloride).
前記着色剤(染顔料)としては、合成又は天然顔料(染料、色素)、例えば、タール色素、酸化鉄系無機顔料、黒酸化鉄レーキ、二酸化チタンなどの白色顔料;パール顔料(雲母チタン系、オキシ塩化ビスマス、魚鱗箔など);赤色223号、橙色201号などの染料;天然色素(コチニール、カルサミンなど)などが挙げられる。 Examples of the colorant (dye pigment) include synthetic or natural pigments (dyes, dyes), for example, white pigments such as tar dyes, iron oxide-based inorganic pigments, black iron oxide lakes, and titanium dioxide; pearl pigments (titanium mica-based, Bismuth oxychloride, fish scale foil, etc.); dyes such as red 223 and orange 201; natural pigments (cochineal, calsamine, etc.) and the like.
さらに添加剤には、pH調整剤(炭酸水素ナトリウムなどの塩基;リン酸一水素ナトリウムなどの酸;ホウ砂など)、キレート剤(クエン酸などのオキシカルボン酸、メタリン酸などのリン酸など)、金属イオン封鎖剤(ポリリン酸塩、エチレンジアミン四酢酸塩など)、固化剤(前記基剤の項で例示の高級アルコール、飽和脂肪酸、ワックス類など)、可溶化剤(ポリオキシエチレン硬化ひまし油など)、可塑剤(カンファー、フタル酸ジブチルなどのフタル酸エステル、アセチルクエン酸トリブチルなどの脂肪族多塩基酸エステルなど)、ゲル化剤(有機変性ベントナイトなど)、増粘剤(前記基剤の項で例示の粘液質など)、有機溶剤(エタノール、ブタノールなどのアルコールなど)、還元剤(チオグリコール酸又はその塩、システインなど)、塩基性剤(アンモニア水、炭酸アンモニウム、エタノールアミンなど)、酸化剤(臭素酸ナトリウム、過酸化水素、過ホウ素酸ナトリウムなど)、防腐剤又は保存料(パラベン、安息香酸ナトリウムなど)、清涼剤(メントールなど)なども含まれる。前記添加剤は、単独で又は二種以上組み合わせて使用できる。 Further additives include pH adjusters (bases such as sodium bicarbonate; acids such as sodium monohydrogen phosphate; borax, etc.), chelating agents (oxycarboxylic acids such as citric acid, phosphoric acids such as metaphosphoric acid, etc.) Sequestering agents (polyphosphate, ethylenediaminetetraacetate, etc.), solidifying agents (higher alcohols, saturated fatty acids, waxes, etc. exemplified in the above-mentioned base), solubilizers (polyoxyethylene hydrogenated castor oil, etc.) , Plasticizers (phthalates such as camphor and dibutyl phthalate, aliphatic polybasic esters such as tributyl acetyl citrate), gelling agents (such as organically modified bentonite), thickeners (in the terms of the base) Exemplified mucus), organic solvent (ethanol, alcohol such as butanol), reducing agent (thioglycolic acid or its salt, system ), Basic agents (ammonia water, ammonium carbonate, ethanolamine, etc.), oxidizing agents (sodium bromate, hydrogen peroxide, sodium perborate, etc.), preservatives or preservatives (paraben, sodium benzoate, etc.) Also included are refreshing agents (such as menthol). The said additive can be used individually or in combination of 2 or more types.
前記添加剤の割合は、化粧料全体に対して、0.001〜40重量%、好ましくは0.01〜30重量%、0.1〜20重量%程度であってもよい。 The proportion of the additive may be about 0.001 to 40% by weight, preferably about 0.01 to 30% by weight, and about 0.1 to 20% by weight with respect to the entire cosmetic.
前記基剤、有効成分及び添加剤は、塩の形態で用いてもよい。このような塩としては、生理的又は薬学上許容できる塩が好ましく、例えば、有機酸塩(例えば、酢酸塩、フマル酸塩、クエン酸塩などのカルボン酸塩;メタンスルホン酸塩などの有機スルホン酸塩など)、無機酸塩(例えば、塩酸塩など)、有機塩基との塩(例えば、トリメチルアミン塩、エタノールアミン塩などの第三級アミンとの塩など)、無機塩基との塩(例えば、アンモニウム塩;ナトリウム塩などのアルカリ金属塩;カルシウム塩などのアルカリ土類金属塩;アルミニウム塩など)が挙げられる。 The base, active ingredient and additive may be used in the form of a salt. Such salts are preferably physiologically or pharmaceutically acceptable salts, such as organic acid salts (for example, carboxylates such as acetate, fumarate and citrate; organic sulfones such as methanesulfonate). Acid salts), inorganic acid salts (eg, hydrochloride salts), salts with organic bases (eg, salts with tertiary amines such as trimethylamine salts, ethanolamine salts, etc.), salts with inorganic bases (eg, Ammonium salts; alkali metal salts such as sodium salts; alkaline earth metal salts such as calcium salts; aluminum salts).
なお、基剤、有効成分及び添加剤は、前記ポリペプチドの特性を損なわない限り、ポリペプチドに対して相互作用性を有していてもよいが、通常、相互作用性(反応性、分解性など)を有しないのが好ましい。 In addition, the base, the active ingredient, and the additive may have an interaction property with the polypeptide as long as the properties of the polypeptide are not impaired, but usually the interaction property (reactivity, degradability). Etc.).
本発明の化粧料は、皮膚などに適用する外用組成物として利用できる。適用部位としては、特に制限されないが、例えば、頭、顔、首、腕、手、胴、足などの種々の部位の外皮の他、口腔内、頭髪、睫、眉毛などの体毛、爪などが例示できる。 The cosmetic of the present invention can be used as an external composition applied to the skin and the like. The application site is not particularly limited. For example, in addition to the outer skin of various parts such as the head, face, neck, arms, hands, torso, and feet, the body hair such as the oral cavity, head hair, eyelids, eyebrows, and nails. It can be illustrated.
本発明の化粧料の形態は、特に制限されず、例えば、液剤(ローション、乳剤、懸濁液など)、半固形剤(ゲル剤、軟膏剤、硬膏剤、クリーム剤など)、固形剤(粉末、ケークなど)などが挙げられる。液剤及び半固形剤は、基材(不織布、織布、紙、ポリマーフィルムなど)に含浸又は塗布した形態、例えば、パック、マスク、ウェットティッシュなどとして用いてもよい。 The form of the cosmetic of the present invention is not particularly limited, and examples thereof include liquids (lotions, emulsions, suspensions, etc.), semi-solids (gels, ointments, plasters, creams, etc.), solids (powder) , Cake, etc.). The liquid agent and the semi-solid agent may be used as a form impregnated or coated on a substrate (nonwoven fabric, woven fabric, paper, polymer film, etc.), for example, a pack, a mask, a wet tissue, or the like.
前記液剤は、溶液、又は分散液(水性液剤に粉末が分散した分散液、水−非水系有機溶媒の二層系液剤の分散液、水−非水系有機溶媒の二層系液剤に粉末が分散した分散液など)であってもよい。また、液剤は、スプレーやエアゾール剤として用いてもよく、スプレー又はエアゾール剤では、噴射される液剤は、霧状であってもよく、泡状であってもよい。なお、エアゾール剤の噴射剤としては、液化ガス(フッ化炭化水素、炭化水素類、液化石油ガス、ジメチルエーテルなど)、圧縮ガス(窒素ガス、二酸化炭素などの圧縮不活性ガスなど)などが使用できる。 The liquid is a solution or a dispersion (a dispersion in which a powder is dispersed in an aqueous liquid, a dispersion in a two-layer liquid of water-nonaqueous organic solvent, or a dispersion in a two-layer liquid of water-nonaqueous organic solvent. Or a dispersion thereof). Moreover, a liquid agent may be used as a spray or an aerosol agent, and in a spray or an aerosol agent, the sprayed liquid agent may be mist-like or foamy. As the propellant for the aerosol agent, liquefied gas (fluorinated hydrocarbon, hydrocarbons, liquefied petroleum gas, dimethyl ether, etc.), compressed gas (nitrogen gas, compressed inert gas such as carbon dioxide, etc.), etc. can be used. .
化粧料の使用形態としては、基礎化粧料(ローション、化粧水、ジェル状化粧水、乳液、クリーム、美容液など)、メークアップ化粧料(液体又は粉末状ファンデーション、頬紅、アイシャドー、整髪剤など)、入浴料(浴用剤など)、洗浄料(洗顔料、クレンジング剤、石鹸、ボディーシャンプー、シャンプー、リンス、コンディショナーなど)などが挙げられる。 Cosmetic usage forms include basic cosmetics (lotions, lotions, gel lotions, emulsions, creams, cosmetics, etc.), makeup cosmetics (liquid or powder foundations, blusher, eye shadows, hairdressing agents, etc.) ), Bathing charges (bath preparations, etc.), cleaning agents (face wash, cleansing agent, soap, body shampoo, shampoo, rinse, conditioner, etc.).
また、化粧料には、適用部位や用途(機能)に応じて、例えば、頭皮・頭髪用化粧料(シャンプー、ヘアリンス、ヘアトリートメント、毛髪用美容液、ヘアスタイリング剤、パーマ液、コールドウェーブローション、染毛料など)、部分用化粧料[アイライナー、マスカラなどのアイメーク用化粧料;リップクリーム、口唇用美容液、口紅、リップグロス、口紅用リムーバーなどの口唇用化粧料;口腔用化粧料(歯磨き剤、洗口剤、口中清涼剤など);爪用化粧料(爪用美容液、ネールエナメル、エナメルリムーバーなど)など]、日焼け・日焼け止め用化粧料、しみそばかす用化粧料、ニキビ用化粧料、防臭化粧料(制汗剤など)なども含まれる。 For cosmetics, depending on the application site and application (function), for example, scalp and hair cosmetics (shampoo, hair rinse, hair treatment, hair serum, hair styling agent, perm solution, cold wave lotion, Hair dyes, etc.), partial cosmetics (eyeliner, mascara and other eye makeup cosmetics; lip cream, lip serum, lipstick, lip gloss, lipstick remover, etc .; oral cosmetics (toothpaste) Cosmetics, mouthwashes, mouth fresheners, etc .; nail cosmetics (nail serum, nail enamel, enamel remover, etc.)], sunscreen / sunscreen cosmetics, stain freckles cosmetics, acne cosmetics Also included are deodorant cosmetics (antiperspirants, etc.).
本発明の化粧料の用法及び用量は、化粧料の種類(用途)や形態などに応じて選択でき、例えば、1日あたり1〜5回程度、所定部位に適用できる。例えば、パーマ液などの用途では、1週間乃至数ヶ月に1〜3回程度、所定部位に適用でき、エナメルなどの用途では、1日乃至1週間に1〜10回程度、所定部位に適用できる。また、洗浄料、毛髪料(リンス、コンディショナー、トリートメント、パーマ液など)などの用途では、化粧料を適用後、水や湯などにより洗い落としてもよい。 The usage and dosage of the cosmetic of the present invention can be selected according to the type (use) and form of the cosmetic, and can be applied to a predetermined site, for example, about 1 to 5 times per day. For example, in applications such as perm liquid, it can be applied to a predetermined site about 1 to 3 times a week to several months, and in applications such as enamel, it can be applied to a predetermined site about 1 to 10 times a day to a week. . Further, in applications such as cleaning materials and hair materials (rinse, conditioner, treatment, perm solution, etc.), after applying cosmetics, they may be washed away with water or hot water.
本発明の化粧料は、特定のポリペプチドを含んでいるため、種々の化粧料用途、例えば、基礎化粧料、メークアップ化粧料、入浴料、洗浄料などに有用である。また、適用部位や機能に応じて、頭皮・頭髪用化粧料、部分用化粧料(アイメーク用、口唇用、口腔用及び爪用化粧料など)の他、日焼け・日焼け止め化粧料、しみそばかす用化粧料、ニキビ用化粧料、防臭化粧料などに利用できる。 Since the cosmetic of the present invention contains a specific polypeptide, it is useful for various cosmetic applications, for example, basic cosmetics, makeup cosmetics, bathing cosmetics, washings and the like. In addition to scalp / hair cosmetics, partial cosmetics (for eye makeup, lips, oral and nail cosmetics, etc.), sunscreen / sunscreen cosmetics, and freckles depending on the application site and function It can be used for cosmetics, acne cosmetics, deodorant cosmetics and the like.
以下に、実施例に基づいて本発明をより詳細に説明するが、本発明はこれらの実施例によって限定されるものではない。 Hereinafter, the present invention will be described in more detail based on examples, but the present invention is not limited to these examples.
製造例1
式:H-(Pro-Pro-Gly)10-OH(配列番号:1)で示されるペプチド((株)ペプチド研究所)5mg(0.002mmol)を2mLのジメチルスルホキシドに懸濁し、室温で撹拌した。この混合液に、0.31mg(0.0024mmol)のジイソプロピルエチルアミン、0.32mg(0.0024mmol)の1−ヒドロキシベンゾトリアゾール、0.46mg(0.0024mmol)の1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド塩酸塩を添加して、さらに室温で7日間撹拌を続けた。
Production Example 1
5 mg (0.002 mmol) of a peptide represented by the formula: H- (Pro-Pro-Gly) 10 -OH (SEQ ID NO: 1) (Peptide Institute, Inc.) was suspended in 2 mL of dimethyl sulfoxide and stirred at room temperature. . To this mixture, 0.31 mg (0.0024 mmol) diisopropylethylamine, 0.32 mg (0.0024 mmol) 1-hydroxybenzotriazole, 0.46 mg (0.0024 mmol) 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimide. Hydrochloride was added and stirring was continued for an additional 7 days at room temperature.
反応溶液を水で20倍に希釈し、ゲルパーミエーションクロマトグラフィー(アマシャム・バイオサイエンス(株)製、AKTApurifierシステム、カラム:Superdex 200 HR 10/30、流速:0.5mL/min、溶離液:150mMのNaClを含む10mM phosphate buffer(pH 7.4))に供したところ、分子量が4万〜20万の範囲にポリペプチドのピークが認められた。分子量はアマシャム・バイオサイエンス(株)製のGel Filtration LMW Calibration Kit及びGel Filtration HMW Calibration Kitを標準物質として使用し、算出した。 The reaction solution was diluted 20-fold with water, and gel permeation chromatography (Amersham Biosciences, AKTApurifier system, column: Superdex 200 HR 10/30, flow rate: 0.5 mL / min, eluent: 150 mM When subjected to a 10 mM phosphate buffer (pH 7.4) containing NaCl, a polypeptide peak was observed in the molecular weight range of 40,000 to 200,000. The molecular weight was calculated by using Gel Filtration LMW Calibration Kit and Gel Filtration HMW Calibration Kit manufactured by Amersham Biosciences as standard substances.
得られた反応溶液を水で5倍に希釈し、水に対して3日間透析して、縮合剤などの試薬と未反応モノマーを除去した。得られたポリペプチドの円二色性スペクトルを測定したところ、227nmに正のコットン効果、199nmに負のコットン効果が観測され、3重らせん構造を形成していることが確認された。得られたポリペプチドをポリペプチド(Ia)とする。 The obtained reaction solution was diluted 5 times with water and dialyzed against water for 3 days to remove reagents such as a condensing agent and unreacted monomers. When the circular dichroism spectrum of the obtained polypeptide was measured, a positive cotton effect was observed at 227 nm and a negative cotton effect was observed at 199 nm, confirming the formation of a triple helical structure. The obtained polypeptide is designated as polypeptide (Ia).
製造例2
式:H-(Pro-Pro-Gly)5-OH(配列番号:2)で示されるペプチド鎖をペプチド自動合成装置を用いて固相合成法により合成した。すなわち、4−(Nα−9−(フルオレニルメトキシカルボニル)−グリシン)−オキシメチル−フェノキシ−メチル基を0.65mmol/g (樹脂)の割合で含むスチレン−ジビニルベンゼン共重合体〔スチレンとジビニルベンゼンの構成モル比:99対1〕からなる粒状樹脂〔米国アプライド・バイオシステムズ社製、HMPグリシン〕0.1mmolを用い、目的とするペプチドのカルボキシル末端からアミノ末端に向かって順次対応するアミノ酸を結合させた。結合反応において、アミノ酸として、米国アプライド・バイオシステムズ社製のNα−9−(フルオレニルメトキシカルボニル)−L−プロリン〔Fmocプロリン〕、Nα−9−(フルオレニルメトキシカルボニル)−グリシン〔Fmocグリシン〕を、各結合ステップについてそれぞれ1mmolずつ用いた。
Production Example 2
A peptide chain represented by the formula: H- (Pro-Pro-Gly) 5 -OH (SEQ ID NO: 2) was synthesized by a solid phase synthesis method using an automatic peptide synthesizer. That, 4- (N α -9- (fluorenyl methoxy carbonyl) - glycine) - divinylbenzene copolymer [styrene - oxymethyl - phenoxy - styrene in a proportion of methyl groups of 0.65 mmol / g (resin) Using 0.1 mmol of granular resin (HMP glycine, manufactured by Applied Biosystems, Inc.) consisting of a divinylbenzene constituent molar ratio: 99 to 1], the corresponding amino acids are sequentially added from the carboxyl terminus to the amino terminus of the target peptide. Combined. In the binding reaction, N α -9- (fluorenylmethoxycarbonyl) -L-proline [Fmoc proline], N α -9- (fluorenylmethoxycarbonyl) -glycine manufactured by Applied Biosystems, Inc. [Fmoc glycine] was used in an amount of 1 mmol for each binding step.
得られたペプチド樹脂(ペプチドを結合した樹脂)を、10mLのジメチルホルムアミドに懸濁し、50mg(0.5mmol)の無水コハク酸と13mg(0.1mmol)のジイソプロピルエチルアミンを加えて、室温で12時間反応した。その後、メチルアルコールとジクロロメタンで交互に洗浄し、減圧乾燥した。 The obtained peptide resin (resin bonded with peptide) was suspended in 10 mL of dimethylformamide, 50 mg (0.5 mmol) of succinic anhydride and 13 mg (0.1 mmol) of diisopropylethylamine were added, and the mixture was reacted at room temperature for 12 hours. . Then, it washed with methyl alcohol and dichloromethane alternately, and dried under reduced pressure.
得られたペプチド樹脂を、5%の水を含むトリフルオロ酢酸10mLで3時間処理した。得られた溶液をジエチルエーテルに加えて生じる沈殿をさらに数回ジエチルエーテルで洗浄して、ペプチドの脱保護と樹脂からの脱離を行った。粗生成物を、PD10カラム(アマシャム・バイオサイエンス(株)製)で精製してペプチドを得た。得られた精製ペプチドをアマシャム・バイオサイエンス(株)製「AKTA explorer10XT」〔カラム:ミリポア(株)製「ノバパックC18」 3.9mmφ×150mm、移動相:トリフルオロ酢酸を0.05容量%含有するアセトニトリルと水の混合溶媒(アセトニトリル濃度を30分間で5容量%から50容量%に直線的に変化させた)、流速1.0mL/min〕に付したところ、リテンションタイム14.5minに単一のピ−クが示された。FAB法マススペクトルにより求めた精製ペプチドの分子量は1375であった(理論値:1374.52)。 The obtained peptide resin was treated with 10 mL of trifluoroacetic acid containing 5% water for 3 hours. The resulting solution was added to diethyl ether, and the resulting precipitate was further washed several times with diethyl ether to deprotect the peptide and desorb from the resin. The crude product was purified with a PD10 column (manufactured by Amersham Biosciences) to obtain a peptide. The purified peptide thus obtained was made into “AKTA explorer10XT” manufactured by Amersham Biosciences Inc. [Column: “Novapack C18” manufactured by Millipore Co., Ltd., 3.9 mmφ × 150 mm, mobile phase: acetonitrile and water containing 0.05% by volume of trifluoroacetic acid. (Acetonitrile concentration was linearly changed from 5 vol% to 50 vol% over 30 minutes), and a flow rate of 1.0 mL / min) showed a single peak at a retention time of 14.5 min. It was done. The molecular weight of the purified peptide determined by FAB mass spectrum was 1375 (theoretical value: 1374.52).
1.4mg(0.001mmol)のHOOC-(CH2)2-CO-(Pro-Pro-Gly)5-OHと、0.06mg (0.001mmol)のエチレンジアミンとを0.05mLの水に懸濁し、混合液に、0.32mg(0.0024mmol)の1−ヒドロキシベンゾトリアゾール、4.6mg(0.024mmol)の1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド塩酸塩を添加して、室温で3日間振盪した。 Suspend 1.4 mg (0.001 mmol) HOOC- (CH 2 ) 2 -CO- (Pro-Pro-Gly) 5 -OH and 0.06 mg (0.001 mmol) ethylenediamine in 0.05 mL water, 0.32 mg (0.0024 mmol) of 1-hydroxybenzotriazole, 4.6 mg (0.024 mmol) of 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimide hydrochloride were added and shaken at room temperature for 3 days.
反応溶液を水で100倍に希釈し、ゲルパーミエーションクロマトグラフィー(アマシャム・バイオサイエンス(株)製、AKTApurifierシステム、カラム:Superdex 200 HR 10/30、流速:0.5mL/min、溶離液:150mMのNaClを含む10mM phosphate buffer(pH 7.4))により分子量を測定したところ、分子量が3万〜20万の範囲にポリペプチドのピークが認められた。分子量はアマシャム・バイオサイエンス(株)製のGel Filtration LMW Calibration Kit及びGel Filtration HMW Calibration Kitを標準物質として使用し、算出した。 The reaction solution was diluted 100 times with water, and gel permeation chromatography (Amersham Biosciences, AKTApurifier system, column: Superdex 200 HR 10/30, flow rate: 0.5 mL / min, eluent: 150 mM) When the molecular weight was measured using a 10 mM phosphate buffer (pH 7.4) containing NaCl, a polypeptide peak was observed in the molecular weight range of 30,000 to 200,000. The molecular weight was calculated by using Gel Filtration LMW Calibration Kit and Gel Filtration HMW Calibration Kit manufactured by Amersham Biosciences as standard substances.
得られた反応溶液を水で5倍に希釈し、水に対して3日間透析して、縮合剤などの試薬と未反応モノマーを除去した。得られたポリペプチドの円二色性スペクトルを測定したところ、228nmに正のコットン効果、198nmに負のコットン効果が観測され、3重らせん構造を形成していることが確認された。得られたポリペプチドをポリペプチド(Ib)とする。 The obtained reaction solution was diluted 5 times with water and dialyzed against water for 3 days to remove reagents such as a condensing agent and unreacted monomers. When the circular dichroism spectrum of the obtained polypeptide was measured, a positive cotton effect was observed at 228 nm and a negative cotton effect was observed at 198 nm, confirming the formation of a triple helical structure. The obtained polypeptide is designated as polypeptide (Ib).
製造例3
式:H-(Pro-Hyp-Gly)10-OH(配列番号:3)で示されるペプチド((株)ペプチド研究所)5mg(0.0016mmol)を2mLのジメチルスルホキシドに懸濁し、室温で撹拌した。この混合液に、0.23mg(0.0018mmol)のジイソプロピルエチルアミン、0.24mg(0.0018mmol)の1−ヒドロキシベンゾトリアゾール、0.65mg(0.0034mmol)の1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド塩酸塩を添加して、さらに室温で7日間撹拌を続けた。
Production Example 3
5 mg (0.0016 mmol) of a peptide represented by the formula: H- (Pro-Hyp-Gly) 10 -OH (SEQ ID NO: 3) (Peptide Institute, Inc.) was suspended in 2 mL of dimethyl sulfoxide and stirred at room temperature. . To this mixture was added 0.23 mg (0.0018 mmol) diisopropylethylamine, 0.24 mg (0.0018 mmol) 1-hydroxybenzotriazole, 0.65 mg (0.0034 mmol) 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimide. Hydrochloride was added and stirring was continued for an additional 7 days at room temperature.
反応溶液を水で20倍に希釈し、ゲルパーミエーションクロマトグラフィー(アマシャム・バイオサイエンス(株)製、AKTApurifierシステム、カラム:Superdex 200 HR 10/30、流速:0.5mL/min、溶離液:150mMのNaClを含む10mM phosphate buffer(pH 7.4))に供したところ、分子量が6万〜20万以上の範囲にポリペプチドのピークが認められた。分子量はアマシャム・バイオサイエンス(株)製のGel Filtration LMW Calibration Kit及びGel Filtration HMW Calibration Kitを標準物質として使用し、算出した。 The reaction solution was diluted 20-fold with water, and gel permeation chromatography (Amersham Biosciences, AKTApurifier system, column: Superdex 200 HR 10/30, flow rate: 0.5 mL / min, eluent: 150 mM When subjected to a 10 mM phosphate buffer (pH 7.4) containing NaCl, a polypeptide peak was observed in the molecular weight range of 60,000 to 200,000 or more. The molecular weight was calculated by using Gel Filtration LMW Calibration Kit and Gel Filtration HMW Calibration Kit manufactured by Amersham Biosciences as standard substances.
得られた反応溶液を水で5倍に希釈し、水に対して3日間透析して、縮合剤などの試薬と未反応モノマーを除去した。得られたポリペプチドの円二色性スペクトルを測定したところ、225nmに正のコットン効果、197nmに負のコットン効果が観測され、3重らせん構造を形成していることが確認された。得られたポリペプチドをポリペプチド(Ic)とする。 The obtained reaction solution was diluted 5 times with water and dialyzed against water for 3 days to remove reagents such as a condensing agent and unreacted monomers. When the circular dichroism spectrum of the obtained polypeptide was measured, a positive cotton effect was observed at 225 nm and a negative cotton effect was observed at 197 nm, confirming the formation of a triple helical structure. The obtained polypeptide is designated as polypeptide (Ic).
得られたポリペプチド(Ic)の水懸濁液をフッ素樹脂(ポリテトラフルオロエチレン)シート上に流延した後、風乾することによりキャストフィルムを作製した。このフィルムに金を蒸着した後、走査型電子顕微鏡で観測すると、図1に示すような繊維状の構造物が観測された。 The obtained polypeptide (Ic) suspension in water was cast on a fluororesin (polytetrafluoroethylene) sheet and then air-dried to prepare a cast film. When gold was deposited on this film and observed with a scanning electron microscope, a fibrous structure as shown in FIG. 1 was observed.
製造例4
式:H-(Pro-Pro-Gly)5-OH(配列番号:2)で示されるペプチド((株)ペプチド研究所)3.5mg(0.0026mmol)と、実施例2と同様の方法で合成した0.92mg(0.0011mmol)のH-(Val-Pro-Gly-Val-Gly)2-OH(配列番号:4)とを所定の割合(70モル%:30モル%)で1.5mLのジメチルスルホキシドに懸濁し、室温で撹拌した。この混合液に、0.52mg(0.0040mmol)のジイソプロピルエチルアミン、0.51mg(0.0038mmol)の1−ヒドロキシベンゾトリアゾール、1.45mg(0.0076mmol)の1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド塩酸塩を添加して、さらに室温で7日間撹拌を続けた。
Production Example 4
The peptide represented by the formula: H- (Pro-Pro-Gly) 5 -OH (SEQ ID NO: 2) (Peptide Institute, Inc.) 3.5 mg (0.0026 mmol) was synthesized in the same manner as in Example 2. 0.92 mg (0.0011 mmol) of H- (Val-Pro-Gly-Val-Gly) 2 —OH (SEQ ID NO: 4) at a predetermined ratio (70 mol%: 30 mol%) to 1.5 mL of dimethyl sulfoxide Suspended and stirred at room temperature. To this mixture, 0.52 mg (0.0040 mmol) diisopropylethylamine, 0.51 mg (0.0038 mmol) 1-hydroxybenzotriazole, 1.45 mg (0.0076 mmol) 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimide. Hydrochloric acid was added and stirring was continued for an additional 7 days at room temperature.
反応溶液を水で20倍に希釈し、ゲルパーミエーションクロマトグラフィー(アマシャム・バイオサイエンス(株)製、AKTApurifierシステム、カラム:Superdex 200 HR 10/30、流速:0.5mL/min、溶離液:150mMのNaClを含む10mM phosphate buffer(pH 7.4))により分子量を測定したところ、分子量が8万〜45万の範囲にポリペプチドのピークが認められた。分子量はアマシャム・バイオサイエンス(株)製のGel Filtration LMW Calibration Kit及びGel Filtration HMW Calibration Kitを標準物質として使用し、算出した。 The reaction solution was diluted 20-fold with water, and gel permeation chromatography (Amersham Biosciences, AKTApurifier system, column: Superdex 200 HR 10/30, flow rate: 0.5 mL / min, eluent: 150 mM When the molecular weight was measured with a 10 mM phosphate buffer (pH 7.4) containing NaCl, a polypeptide peak was observed in the molecular weight range of 80,000 to 450,000. The molecular weight was calculated by using Gel Filtration LMW Calibration Kit and Gel Filtration HMW Calibration Kit manufactured by Amersham Biosciences as standard substances.
得られた反応溶液を水で5倍に希釈し、水に対して3日間透析して、縮合剤などの試薬と未反応モノマーを除去した。得られたポリペプチドの円二色性スペクトルを測定したところ、227nmに正のコットン効果、198nmに負のコットン効果が観測され、3重らせん構造を形成していることが確認された。得られたポリペプチドをポリペプチド(Id)とする。 The obtained reaction solution was diluted 5 times with water and dialyzed against water for 3 days to remove reagents such as a condensing agent and unreacted monomers. When the circular dichroism spectrum of the obtained polypeptide was measured, a positive cotton effect was observed at 227 nm and a negative cotton effect was observed at 198 nm, confirming the formation of a triple helical structure. Let the obtained polypeptide be polypeptide (Id).
得られたポリペプチドの水懸濁液をフッ素樹脂(ポリテトラフルオロエチレン)シート上に流延した後、風乾することによりキャストフィルムを作製した。このフィルムを、150mMのNaClを含む10mM phosphate buffer(pH 7.4)に浸漬するとシート状のゲル状物が得られた。このシート状のゲル状物は、室温では透明であったが、40℃以上の温度で可逆的に白濁した。 The obtained aqueous suspension of the polypeptide was cast on a fluororesin (polytetrafluoroethylene) sheet, and then air-dried to prepare a cast film. When this film was immersed in a 10 mM phosphate buffer (pH 7.4) containing 150 mM NaCl, a sheet-like gel was obtained. This sheet-like gel was transparent at room temperature, but reversibly became cloudy at a temperature of 40 ° C. or higher.
製造例5
式:H-(Pro-Hyp-Gly)5-OH(配列番号:5)で示されるペプチド((株)ペプチド研究所)5mg(0.0033mmol)を2 mLのジメチルスルホキシドに懸濁し、室温で撹拌した。この混合液に、0.44mg(0.0034mmol)のジイソプロピルエチルアミン、0.46mg(0.0033mmol)の1−ヒドロキシベンゾトリアゾール、1.3mg(0.0068mmol)の1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド塩酸塩を添加して、さらに室温で14日間撹拌を続けた。
Production Example 5
5 mg (0.0033 mmol) of the peptide represented by the formula: H- (Pro-Hyp-Gly) 5 -OH (SEQ ID NO: 5) (Peptide Institute, Inc.) is suspended in 2 mL of dimethyl sulfoxide and stirred at room temperature. did. To this mixture, 0.44 mg (0.0034 mmol) diisopropylethylamine, 0.46 mg (0.0033 mmol) 1-hydroxybenzotriazole, 1.3 mg (0.0068 mmol) 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimide. Hydrochloride was added and stirring was continued for an additional 14 days at room temperature.
反応溶液を水で20倍に希釈し、ゲルパーミエーションクロマトグラフィー(アマシャム・バイオサイエンス(株)製、AKTApurifierシステム、カラム:Superdex 200 HR 10/30、流速:0.5mL/min、溶離液:150mMのNaClを含む10mM phosphate buffer(pH 7.4))に供したところ、分子量が4万〜10万以上の範囲にポリペプチドのピークが認められた。分子量はアマシャム・バイオサイエンス(株)製のGel Filtration LMW Calibration Kit及びGel Filtration HMW Calibration Kitを標準物質として使用し、算出した。 The reaction solution was diluted 20-fold with water, and gel permeation chromatography (Amersham Biosciences, AKTApurifier system, column: Superdex 200 HR 10/30, flow rate: 0.5 mL / min, eluent: 150 mM When subjected to a 10 mM phosphate buffer (pH 7.4) containing NaCl, a polypeptide peak was observed in the molecular weight range of 40,000 to 100,000. The molecular weight was calculated by using Gel Filtration LMW Calibration Kit and Gel Filtration HMW Calibration Kit manufactured by Amersham Biosciences as standard substances.
得られた反応溶液を水で5倍に希釈し、水に対して3日間透析して、縮合剤などの試薬と未反応モノマーを除去した。得られたポリペプチドの円二色性スペクトルを測定したところ、224nmに正のコットン効果、199nmに負のコットン効果が観測され、3重らせん構造を形成していることが確認された。得られたポリペプチドをポリペプチド(Ie)とする。 The obtained reaction solution was diluted 5 times with water and dialyzed against water for 3 days to remove reagents such as a condensing agent and unreacted monomers. When the circular dichroism spectrum of the obtained polypeptide was measured, a positive cotton effect was observed at 224 nm and a negative cotton effect was observed at 199 nm, confirming the formation of a triple helical structure. The obtained polypeptide is designated as polypeptide (Ie).
製造例6
5mg(0.0016mmol)の式:H-(Pro-Hyp-Gly)10-OH(配列番号:3)で示されるペプチド((株)ペプチド研究所)を0.5mLの10mMリン酸塩緩衝液(8.1mMのNa2HPO4・12H2O、1.5mMのKH2PO4、2.7mMのKCl、pH 7.4)に溶解し、20℃で撹拌した。この溶液に、0.24mg(0.0018mmol)の1−ヒドロキシベンゾトリアゾール、31mg(0.16mmol)の1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド塩酸塩を添加して、さらに20℃で24時間撹拌を続けた。
Production Example 6
5 mg (0.0016 mmol) of a peptide represented by the formula: H- (Pro-Hyp-Gly) 10 -OH (SEQ ID NO: 3) (Peptide Institute, Inc.) was added to 0.5 mL of 10 mM phosphate buffer (8.1 It was dissolved in mM Na 2 HPO 4 · 12H 2 O, 1.5 mM KH 2 PO 4 , 2.7 mM KCl, pH 7.4) and stirred at 20 ° C. To this solution was added 0.24 mg (0.0018 mmol) 1-hydroxybenzotriazole, 31 mg (0.16 mmol) 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimide hydrochloride and a further 24 ° C. at 24 ° C. Stirring was continued for hours.
反応溶液を水で60倍に希釈し、ゲルパーミエーションクロマトグラフィー(アマシャム・バイオサイエンス(株)製、AKTApurifierシステム、カラム:Superose 6 HR 10/30、流速:0.5mL/min、溶離液:150mMのNaClを含む10mM リン酸塩緩衝液(pH 7.4))に供したところ、平均分子量40万に相当するポリペプチドのピークが認められた。分子量はアマシャム・バイオサイエンス(株)製のGel Filtration LMW Calibration Kit及びGel Filtration HMW Calibration Kitを標準物質として使用し、算出した。 The reaction solution was diluted 60 times with water, and gel permeation chromatography (Amersham Biosciences, AKTApurifier system, column: Superose 6 HR 10/30, flow rate: 0.5 mL / min, eluent: 150 mM) When subjected to a 10 mM phosphate buffer solution (pH 7.4) containing NaCl, a polypeptide peak corresponding to an average molecular weight of 400,000 was observed. The molecular weight was calculated by using Gel Filtration LMW Calibration Kit and Gel Filtration HMW Calibration Kit manufactured by Amersham Biosciences as standard substances.
得られた反応溶液を水で5倍に希釈し、水に対して3日間透析して、縮合剤などの試薬と未反応モノマーを除去した。得られたポリペプチドの円二色性スペクトルを測定したところ、225nmに正のコットン効果、197nmに負のコットン効果が観測され、3重らせん構造を形成していることが確認された。得られたポリペプチドをポリペプチド(If)とする。 The obtained reaction solution was diluted 5 times with water and dialyzed against water for 3 days to remove reagents such as a condensing agent and unreacted monomers. When the circular dichroism spectrum of the obtained polypeptide was measured, a positive cotton effect was observed at 225 nm and a negative cotton effect was observed at 197 nm, confirming the formation of a triple helical structure. The obtained polypeptide is designated as polypeptide (If).
製造例7
式:H-(Pro-Hyp-Gly)1-OHで示されるペプチド((株)ペプチド研究所)1gを20mLの10mMリン酸塩緩衝液(pH7.4)に溶解し、473mgの1−ヒドロキシベンゾトリアゾール、3.35gの1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド塩酸塩を加えて、4℃で2時間、その後20℃で46時間撹拌を続けた。反応液をミリQ水(超純水)に対して48時間透析した。
Production Example 7
1 g of a peptide represented by the formula: H- (Pro-Hyp-Gly) 1 -OH (Peptide Institute, Inc.) was dissolved in 20 mL of 10 mM phosphate buffer (pH 7.4) to obtain 473 mg of 1-hydroxy. Benzotriazole, 3.35 g 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimide hydrochloride was added and stirring was continued at 4 ° C. for 2 hours and then at 20 ° C. for 46 hours. The reaction solution was dialyzed against Milli Q water (ultra pure water) for 48 hours.
得られた透析後の溶液を水で50倍に希釈し、ゲルパーミエーションクロマトグラフィー(アマシャム・バイオサイエンス(株)製、AKTApurifierシステム、カラム:Superdex 200 HR 10/30、流速:0.5mL/min、溶離液:150mMのNaClを含む10mM phosphate buffer(pH 7.4))に供したところ、分子量が10万〜60万の範囲にポリペプチドのピークが認められた。 The obtained dialyzed solution was diluted 50 times with water, and gel permeation chromatography (Amersham Biosciences, AKTApurifier system, column: Superdex 200 HR 10/30, flow rate: 0.5 mL / min, Eluent: A 10 mM phosphate buffer (pH 7.4) containing 150 mM NaCl was used, and a polypeptide peak was observed in the molecular weight range of 100,000 to 600,000.
また、得られた透析後の溶液を水で100倍に希釈し、円二色性スペクトルを測定したところ、225nmに正のコットン効果、198nmに負のコットン効果が観測され、3重らせん構造を形成していることが確認された。 Moreover, when the obtained solution after dialysis was diluted 100 times with water and the circular dichroism spectrum was measured, a positive cotton effect was observed at 225 nm and a negative cotton effect was observed at 198 nm. The formation was confirmed.
式:(Pro-Hyp-Gly)10(配列番号:3)で示されるペプチド((株)ペプチド研究所)の215nmにおける吸光度から検量線を作成し、得られた3重らせん構造を形成するポリペプチドの濃度を測定すると約20mg/mLであった。得られたポリペプチドをポリペプチド(Ih)とする。 A calibration curve was created from the absorbance at 215 nm of the peptide represented by the formula: (Pro-Hyp-Gly) 10 (SEQ ID NO: 3) (Peptide Laboratories, Inc.), and the poly that forms the resulting triple helical structure The peptide concentration measured was about 20 mg / mL. The obtained polypeptide is designated as polypeptide (Ih).
製造例8
式:H-(Pro-Hyp-Gly)4-Pro-Gln-Gly-Ile-Ala-Gly-(Pro-Hyp-Gly)4-OH(配列番号:6)で示されるペプチド鎖を、ペプチド自動合成装置を用いて固相合成法により合成した。すなわち、4−(Nα−9−(フルオレニルメトキシカルボニル)−グリシン)−オキシメチル−フェノキシ−メチル基を0.65mmol/g(樹脂)の割合で含むスチレン−ジビニルベンゼン共重合体〔スチレンとジビニルベンゼンの構成モル比:99対1〕からなる粒状樹脂〔米国アプライド・バイオシステムズ社製、HMPグリシン〕0.1mmolを用い、目的とするペプチドのカルボキシル末端からアミノ末端に向かって順次対応するアミノ酸を結合させた。結合反応において、アミノ酸として、米国アプライド・バイオシステムズ社製のNα−9−(フルオレニルメトキシカルボニル)−L−プロリン〔Fmocプロリン〕、Nα−9−(フルオレニルメトキシカルボニル)−グリシン〔Fmocグリシン〕、Nα−9−(フルオレニルメトキシカルボニル)−Nγ−トリチル−L−グルタミン〔Fmocグルタミン〕、Nα−9−(フルオレニルメトキシカルボニル)−L−イソロイシン〔Fmocイソロイシン〕、Nα−9−(フルオレニルメトキシカルボニル)−L−アラニン〔Fmocアラニン〕、バッケム社製のNα−9−(フルオレニルメトキシカルボニル)−O−t−ブチル−L−ヒドロキシプロリン〔Fmocヒドロキシプロリン〕を、各結合ステップについてそれぞれ1mmolずつ用いた。
Production Example 8
A peptide chain represented by the formula: H- (Pro-Hyp-Gly) 4 -Pro-Gln-Gly-Ile-Ala-Gly- (Pro-Hyp-Gly) 4 -OH (SEQ ID NO: 6) It was synthesized by a solid phase synthesis method using a synthesizer. That, 4- (N α -9- (fluorenyl methoxy carbonyl) - glycine) - divinylbenzene copolymer [styrene - oxymethyl - phenoxy - styrene in a proportion of methyl groups of 0.65 mmol / g (resin) Using 0.1 mmol of a granular resin (HMP glycine, manufactured by Applied Biosystems, USA) consisting of a divinylbenzene constituent molar ratio: 99: 1, the corresponding amino acids are sequentially added from the carboxyl terminus to the amino terminus of the target peptide. Combined. In the binding reaction, N α -9- (fluorenylmethoxycarbonyl) -L-proline [Fmoc proline], N α -9- (fluorenylmethoxycarbonyl) -glycine manufactured by Applied Biosystems, Inc. [Fmoc-glycine], N α -9- (fluorenyl methoxy carbonyl) -N gamma - trityl -L- glutamine [Fmoc-glutamine], N α -9- (fluorenyl methoxy carbonyl) -L- isoleucine [Fmoc isoleucine ], N alpha-9-(fluorenyl methoxy carbonyl) -L- alanine [Fmoc alanine], Bachem Co. N alpha-9-(fluorenyl methoxy carbonyl) -O-t-butyl -L- hydroxyproline [Fmoc hydroxyproline] was used in an amount of 1 mmol for each binding step.
得られたペプチド樹脂を、5%の水を含むトリフルオロ酢酸10mLで3時間処理した。得られた溶液をジエチルエーテルに加えて生じる沈殿をさらに数回ジエチルエーテルで洗浄して、ペプチドの脱保護と樹脂からの脱離を行った。粗生成物を、PD10カラム(アマシャム・バイオサイエンス(株)製)で精製してペプチドを得た。得られた精製ペプチドをアマシャム・バイオサイエンス(株)製「AKTA explorer10XT」〔カラム:ミリポア(株)製「ノバパックC18」 3.9mmφ×150mm、移動相:トリフルオロ酢酸を0.05容量%含有するアセトニトリルと水の混合溶媒(アセトニトリル濃度を30分間で5容量%から50容量%に直線的に変化させた)、流速1.0mL/min〕に付したところ、リテンションタイム12.4minに単一のピ−クが示された。FAB法マススペクトルにより求めた精製ペプチドの分子量は2681.3であった(理論値:2679.9)。 The obtained peptide resin was treated with 10 mL of trifluoroacetic acid containing 5% water for 3 hours. The resulting solution was added to diethyl ether, and the resulting precipitate was further washed several times with diethyl ether to deprotect the peptide and desorb from the resin. The crude product was purified with a PD10 column (manufactured by Amersham Biosciences) to obtain a peptide. The purified peptide thus obtained was made into “AKTA explorer10XT” manufactured by Amersham Biosciences Inc. [Column: “Novapack C18” manufactured by Millipore Co., Ltd., 3.9 mmφ × 150 mm, mobile phase: acetonitrile and water containing 0.05% by volume of trifluoroacetic acid. (Acetonitrile concentration was changed linearly from 5 vol% to 50 vol% over 30 minutes), flow rate 1.0 mL / min), a single peak was shown at a retention time of 12.4 min. It was done. The molecular weight of the purified peptide determined by FAB method mass spectrum was 2681.3 (theoretical value: 2679.9).
2.5mg(0.0009mmol)のH-(Pro-Hyp-Gly)4-Pro-Gln-Gly-Ile-Ala-Gly-(Pro-Hyp-Gly)4-OHを1mLのジメチルスルホキシドに懸濁し、室温で撹拌した。この混合液に、0.12mg(0.0009mmol)のジイソプロピルエチルアミン、0.12mg(0.0009mmol)の1−ヒドロキシベンゾトリアゾール、0.34mg(0.0018mmol)の1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド塩酸塩を添加して、さらに20℃で2日間撹拌を続けた。得られた反応溶液を水で3倍に希釈し、水に対して3日間透析して、縮合剤などの試薬と未反応モノマーを除去し、ポリペプチド(IIa)を得た。ペプチドユニット(4)と(5)の割合((4)/(5))は8/1(88.9/11.1)(モル比)であった。 Suspend 2.5 mg (0.0009 mmol) of H- (Pro-Hyp-Gly) 4 -Pro-Gln-Gly-Ile-Ala-Gly- (Pro-Hyp-Gly) 4 -OH in 1 mL of dimethyl sulfoxide at room temperature Stir with. To this mixture, 0.12 mg (0.0009 mmol) diisopropylethylamine, 0.12 mg (0.0009 mmol) 1-hydroxybenzotriazole, 0.34 mg (0.0018 mmol) 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimide Hydrochloric acid was added and stirring was continued at 20 ° C. for 2 days. The resulting reaction solution was diluted 3 times with water and dialyzed against water for 3 days to remove reagents such as a condensing agent and unreacted monomers to obtain polypeptide (IIa). The ratio of peptide units (4) and (5) ((4) / (5)) was 8/1 (88.9 / 11.1) (molar ratio).
得られたポリペプチド(IIa)をゲルパーミエーションクロマトグラフィー(アマシャム・バイオサイエンス(株)製、AKTApurifierシステム、カラム:Superose 6 HR GL、流速:0.5mL/min、溶離液:150mMのNaClを含む10mM phosphate buffer(pH 7.4))に供したところ、分子量が7万〜100万の範囲にポリペプチドのピークが認められた。分子量はアマシャム・バイオサイエンス(株)製のGel Filtration HMW Calibration Kitを標準物質として使用し、算出した。 The obtained polypeptide (IIa) was subjected to gel permeation chromatography (manufactured by Amersham Biosciences, AKTApurifier system, column: Superose 6 HR GL, flow rate: 0.5 mL / min, eluent: 10 mM containing 150 mM NaCl. When subjected to phosphate buffer (pH 7.4)), a polypeptide peak was observed in the molecular weight range of 70,000 to 1,000,000. The molecular weight was calculated using a Gel Filtration HMW Calibration Kit manufactured by Amersham Biosciences as a standard substance.
得られたポリペプチド(IIa)の円二色性スペクトルを測定したところ、223nmに正のコットン効果、198nmに負のコットン効果が観測され、3重らせん構造を形成していることが確認された。 When the circular dichroism spectrum of the obtained polypeptide (IIa) was measured, a positive cotton effect was observed at 223 nm and a negative cotton effect was observed at 198 nm, confirming the formation of a triple helical structure. .
製造例9
1.2mg(0.00045mmol)の式:H-(Pro-Hyp-Gly)10-OH(配列番号:3)で示されるペプチド((株)ペプチド研究所)と、1.2mg(0.00045mmol)の製造例8で得られた式:H-(Pro-Hyp-Gly)4-Pro-Gln-Gly-Ile-Ala-Gly-(Pro-Hyp-Gly)4-OH(配列番号:6)で示されるペプチドを0.25mLの10mMリン酸塩緩衝液(pH=7.4)に溶解し、0.12mg(0.0009mmol)の1−ヒドロキシベンゾトリアゾール、15.7mg(0.082mmol)の1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド塩酸塩を添加して、さらに20℃で2日間撹拌を続けた。得られた反応溶液を水で10倍に希釈し、水に対して3日間透析して、縮合剤などの試薬と未反応モノマーを除去し、ポリペプチド(IIb)を得た。ペプチドユニット(4)と(5)の割合((4)/(5))は、18/1(94.7/5.3)(モル比)であった。
Production Example 9
1.2 mg (0.00045 mmol) formula: H- (Pro-Hyp-Gly) 10 -OH (SEQ ID NO: 3) peptide represented by Peptide Institute, Inc. and 1.2 mg (0.00045 mmol) production example Peptide obtained by formula 8: H- (Pro-Hyp-Gly) 4 -Pro-Gln-Gly-Ile-Ala-Gly- (Pro-Hyp-Gly) 4 -OH (SEQ ID NO: 6) Is dissolved in 0.25 mL of 10 mM phosphate buffer (pH = 7.4), 0.12 mg (0.0009 mmol) 1-hydroxybenzotriazole, 15.7 mg (0.082 mmol) 1-ethyl-3- (3-dimethylamino) Propyl) -carbodiimide hydrochloride was added and stirring was continued at 20 ° C. for 2 days. The resulting reaction solution was diluted 10-fold with water and dialyzed against water for 3 days to remove reagents such as a condensing agent and unreacted monomers to obtain polypeptide (IIb). The ratio of peptide units (4) and (5) ((4) / (5)) was 18/1 (94.7 / 5.3) (molar ratio).
得られたポリペプチド(IIb)をゲルパーミエーションクロマトグラフィー(アマシャム・バイオサイエンス(株)製、AKTApurifierシステム、カラム:Superose 6 HR GL、流速:0.5mL/min、溶離液:150mMのNaClを含む10mM phosphate buffer(pH 7.4))に供したところ、分子量が14万〜100万の範囲にポリペプチドのピークが認められた。分子量はアマシャム・バイオサイエンス(株)製のGel Filtration HMW Calibration Kitを標準物質として使用し、算出した。 The obtained polypeptide (IIb) was subjected to gel permeation chromatography (Amersham Biosciences, AKTApurifier system, column: Superose 6 HR GL, flow rate: 0.5 mL / min, eluent: 10 mM containing 150 mM NaCl. When subjected to phosphate buffer (pH 7.4), a polypeptide peak was observed in the molecular weight range of 140,000 to 1,000,000. The molecular weight was calculated using a Gel Filtration HMW Calibration Kit manufactured by Amersham Biosciences as a standard substance.
得られたポリペプチド(IIb)の円二色性スペクトルを測定したところ、224nmに正のコットン効果、196nmに負のコットン効果が観測され、3重らせん構造を形成していることが確認された。 When the circular dichroism spectrum of the obtained polypeptide (IIb) was measured, a positive cotton effect was observed at 224 nm and a negative cotton effect was observed at 196 nm, confirming the formation of a triple helical structure. .
製造例10
2.2mg(0.00081mmol)の式:H-(Pro-Hyp-Gly)10-OH(配列番号:3)で示されるペプチド((株)ペプチド研究所)と、0.24mg(0.00009mmol)の製造例8で得られた式:H-(Pro-Hyp-Gly)4-Pro-Gln-Gly-Ile-Ala-Gly-(Pro-Hyp-Gly)4-OH(配列番号:6)で示されるペプチドを0.25mLの10mMリン酸塩緩衝液(pH=7.4)に溶解し、0.12mg(0.0009mmol)の1−ヒドロキシベンゾトリアゾール、15.7mg(0.082mmol)の1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド塩酸塩を添加して、さらに20℃で2日間撹拌を続けた。得られた反応溶液を水で10倍に希釈し、水に対して3日間透析して、縮合剤などの試薬と未反応モノマーを除去し、ポリペプチド(IIc)を得た。ペプチドユニット(4)と(5)の割合((4)/(5))は、98/1(≒99/1)(モル比)であった。
Production Example 10
2.2 mg (0.00081 mmol) formula: H- (Pro-Hyp-Gly) 10 -OH (SEQ ID NO: 3) peptide represented by Peptide Institute, Inc. and 0.24 mg (0.00009 mmol) production example Peptide obtained by formula 8: H- (Pro-Hyp-Gly) 4 -Pro-Gln-Gly-Ile-Ala-Gly- (Pro-Hyp-Gly) 4 -OH (SEQ ID NO: 6) Is dissolved in 0.25 mL of 10 mM phosphate buffer (pH = 7.4), 0.12 mg (0.0009 mmol) 1-hydroxybenzotriazole, 15.7 mg (0.082 mmol) 1-ethyl-3- (3-dimethylamino) Propyl) -carbodiimide hydrochloride was added and stirring was continued at 20 ° C. for 2 days. The obtained reaction solution was diluted 10-fold with water and dialyzed against water for 3 days to remove reagents such as a condensing agent and unreacted monomers to obtain polypeptide (IIc). The ratio of peptide units (4) and (5) ((4) / (5)) was 98/1 (≈99 / 1) (molar ratio).
得られたポリペプチド(IIc)をゲルパーミエーションクロマトグラフィー(アマシャム・バイオサイエンス(株)製、AKTApurifierシステム、カラム:Superose 6 HR GL、流速:0.5mL/min、溶離液:150mMのNaClを含む10mM phosphate buffer(pH 7.4))に供したところ、分子量が14万〜40万の範囲にポリペプチドのピークが認められた。分子量はアマシャム・バイオサイエンス(株)製のGel Filtration HMW Calibration Kitを標準物質として使用し、算出した。 The obtained polypeptide (IIc) was subjected to gel permeation chromatography (Amersham Biosciences, AKTApurifier system, column: Superose 6 HR GL, flow rate: 0.5 mL / min, eluent: 10 mM containing 150 mM NaCl. When subjected to phosphate buffer (pH 7.4), a polypeptide peak was observed in the molecular weight range of 140,000 to 400,000. The molecular weight was calculated using a Gel Filtration HMW Calibration Kit manufactured by Amersham Biosciences as a standard substance.
得られたポリペプチド(IIc)の円二色性スペクトルを測定したところ、224nmに正のコットン効果、197nmに負のコットン効果が観測され、3重らせん構造を形成していることが確認された。 When the circular dichroism spectrum of the obtained polypeptide (IIc) was measured, a positive cotton effect was observed at 224 nm and a negative cotton effect was observed at 197 nm, confirming the formation of a triple helical structure. .
試験例1
製造例8〜10で得られたポリペプチドのそれぞれ0.025mgを、0.05mLの50mMのNaClと10mMのCaCl2を含む50mM Tris/HCl緩衝液(pH=7.5)に溶解した。さらに、同じ緩衝液0.05mLに溶解した200ngのコラゲナーゼ(MMP-1, human rheumatoid synovial fibroblast)を添加し、37℃で24時間静置した。その後、0.1M HCl水溶液を0.01mL添加して、酵素反応を停止した後、150mMのNaClを含む10mM phosphate buffer(pH 7.4)で希釈して、ゲルパーミエーションクロマトグラフィー(アマシャム・バイオサイエンス(株)製、AKTApurifierシステム、カラム:Superose 6 HR GL、流速:0.5mL/min、溶離液:150mMのNaClを含む10mM phosphate buffer(pH 7.4))で分子量分布の変化を測定した。
Test example 1
0.025 mg of each of the polypeptides obtained in Production Examples 8 to 10 was dissolved in 50 mM Tris / HCl buffer (pH = 7.5) containing 0.05 mL of 50 mM NaCl and 10 mM CaCl 2 . Furthermore, 200 ng collagenase (MMP-1, human rheumatoid synovial fibroblast) dissolved in 0.05 mL of the same buffer was added and allowed to stand at 37 ° C. for 24 hours. Then, 0.01 mL of 0.1 M HCl aqueous solution was added to stop the enzyme reaction, and then diluted with 10 mM phosphate buffer (pH 7.4) containing 150 mM NaCl, followed by gel permeation chromatography (Amersham Biosciences) AKTApurifier system, column: Superose 6 HR GL, flow rate: 0.5 mL / min, eluent: change in molecular weight distribution was measured with 10 mM phosphate buffer (pH 7.4) containing 150 mM NaCl.
その結果、製造例8のポリペプチドではコラゲナーゼを加えない場合のピーク分子量約100万が約54万に低下した。同様に製造例9、10のポリペプチドでも、それぞれ約80万が約40万、約70万が約30万に低下した。 As a result, in the polypeptide of Production Example 8, when the collagenase was not added, the peak molecular weight of about 1 million was reduced to about 540,000. Similarly, in the polypeptides of Production Examples 9 and 10, about 800,000 decreased to about 400,000 and about 700,000 decreased to about 300,000, respectively.
製造例11
式:H-(Pro-Hyp-Gly)4-Pro-Leu-Gly-Ile-Ala-Gly-(Pro-Hyp-Gly)4-OH(配列番号:7)で示されるペプチド鎖を、ペプチド自動合成装置を用いて固相合成法により合成した。すなわち、4−(Nα−9−(フルオレニルメトキシカルボニル)−グリシン)−オキシメチル−フェノキシ−メチル基を0.65mmol/g(樹脂)の割合で含むスチレン−ジビニルベンゼン共重合体〔スチレンとジビニルベンゼンの構成モル比:99対1〕からなる粒状樹脂〔米国アプライド・バイオシステムズ社製、HMPグリシン〕0.1mmolを用い、目的とするペプチドのカルボキシル末端からアミノ末端に向かって順次対応するアミノ酸を結合させた。結合反応において、アミノ酸として、米国アプライド・バイオシステムズ社製のNα−9−(フルオレニルメトキシカルボニル)−L−プロリン〔Fmocプロリン〕、Nα−9−(フルオレニルメトキシカルボニル)−グリシン〔Fmocグリシン〕、Nα−9−(フルオレニルメトキシカルボニル)−L−ロイシン〔Fmocロイシン〕、Nα−9−(フルオレニルメトキシカルボニル)−L−イソロイシン〔Fmocイソロイシン〕、Nα−9−(フルオレニルメトキシカルボニル)−L−アラニン〔Fmocアラニン〕、バッケム社製のNα−9−(フルオレニルメトキシカルボニル)−O−t−ブチル−L−ヒドロキシプロリン〔Fmocヒドロキシプロリン〕を、各結合ステップについてそれぞれ1mmolずつ用いた。
Production Example 11
The peptide chain represented by the formula: H- (Pro-Hyp-Gly) 4 -Pro-Leu-Gly-Ile-Ala-Gly- (Pro-Hyp-Gly) 4 -OH (SEQ ID NO: 7) It was synthesized by a solid phase synthesis method using a synthesizer. That, 4- (N α -9- (fluorenyl methoxy carbonyl) - glycine) - divinylbenzene copolymer [styrene - oxymethyl - phenoxy - styrene in a proportion of methyl groups of 0.65 mmol / g (resin) Using 0.1 mmol of a granular resin (HMP glycine, manufactured by Applied Biosystems, USA) consisting of a divinylbenzene constituent molar ratio: 99: 1, the corresponding amino acids are sequentially added from the carboxyl terminus to the amino terminus of the target peptide. Combined. In the binding reaction, N α -9- (fluorenylmethoxycarbonyl) -L-proline [Fmoc proline], N α -9- (fluorenylmethoxycarbonyl) -glycine manufactured by Applied Biosystems, Inc. [Fmoc glycine], N [ alpha ] -9- (fluorenylmethoxycarbonyl) -L-leucine [Fmoc leucine], N [ alpha ] -9- (fluorenylmethoxycarbonyl) -L-isoleucine [Fmoc isoleucine], N [ alpha ]- 9- (fluorenyl methoxy carbonyl) -L- alanine [Fmoc alanine], Bachem Co. N alpha-9-(fluorenyl methoxy carbonyl) -O-t-butyl -L- hydroxyproline [Fmoc-hydroxyproline] Was used for each conjugation step.
得られたペプチド樹脂を、5%の水を含むトリフルオロ酢酸10mLで3時間処理した。得られた溶液をジエチルエーテルに加えて生じる沈殿をさらに数回ジエチルエーテルで洗浄して、ペプチドの脱保護と樹脂からの脱離を行った。粗生成物を、PD10カラム(アマシャム・バイオサイエンス(株)製)で精製してペプチドを得た。得られた精製ペプチドをアマシャム・バイオサイエンス(株)製「AKTA explorer10XT」〔カラム:ミリポア(株)製「ノバパックC18」 3.9mmφ×150mm、移動相:トリフルオロ酢酸を0.05容量%含有するアセトニトリルと水の混合溶媒(アセトニトリル濃度を30分間で5容量%から50容量%に直線的に変化させた)、流速1.0mL/min〕に付したところ、リテンションタイム15minに単一のピ−クが示された。FAB法マススペクトルにより求めた精製ペプチドの分子量は2666.3であった(理論値:2664.9)。 The obtained peptide resin was treated with 10 mL of trifluoroacetic acid containing 5% water for 3 hours. The resulting solution was added to diethyl ether, and the resulting precipitate was further washed several times with diethyl ether to deprotect the peptide and desorb from the resin. The crude product was purified with a PD10 column (manufactured by Amersham Biosciences) to obtain a peptide. The purified peptide thus obtained was made into “AKTA explorer10XT” manufactured by Amersham Biosciences Inc. [Column: “Novapack C18” manufactured by Millipore Co., Ltd., 3.9 mmφ × 150 mm, mobile phase: acetonitrile and water containing 0.05% by volume of trifluoroacetic acid. (Acetonitrile concentration was changed linearly from 5 vol% to 50 vol% over 30 minutes), and a flow rate of 1.0 mL / min) showed a single peak at a retention time of 15 min. It was. The molecular weight of the purified peptide determined by FAB method mass spectrum was 2666.3 (theoretical value: 2664.9).
1.2mg(0.00045mmol)のH-(Pro-Hyp-Gly)4-Pro-Leu-Gly-Ile-Ala-Gly-(Pro-Hyp-Gly)4-OHを0.25mLの10mMリン酸塩緩衝液(pH=7.4)に溶解し、0.12mg(0.0009mmol)の1−ヒドロキシベンゾトリアゾール、15.7mg(0.082mmol)の1−エチル−3−(3−ジメチルアミノプロピル)−カルボジイミド塩酸塩を添加して、さらに20℃で2日間撹拌を続けた。得られた反応溶液を水で10倍に希釈し、水に対して3日間透析して、縮合剤などの試薬と未反応モノマーを除去し、ポリペプチド(IId)を得た。ペプチドユニット(4)と(5)の割合((4)/(5))は、8/1(88.9/11.1)(モル比)であった。 1.2 mg (0.00045 mmol) H- (Pro-Hyp-Gly) 4 -Pro-Leu-Gly-Ile-Ala-Gly- (Pro-Hyp-Gly) 4 -OH in 0.25 mL of 10 mM phosphate buffer (PH = 7.4) and 0.12 mg (0.0009 mmol) 1-hydroxybenzotriazole, 15.7 mg (0.082 mmol) 1-ethyl-3- (3-dimethylaminopropyl) -carbodiimide hydrochloride were added. Stirring was further continued at 20 ° C. for 2 days. The resulting reaction solution was diluted 10-fold with water and dialyzed against water for 3 days to remove reagents such as a condensing agent and unreacted monomers to obtain polypeptide (IId). The ratio of peptide units (4) and (5) ((4) / (5)) was 8/1 (88.9 / 11.1) (molar ratio).
得られたポリペプチド(IId)をゲルパーミエーションクロマトグラフィー(アマシャム・バイオサイエンス(株)製、AKTApurifierシステム、カラム:Superose 6 HR GL、流速:0.5mL/min、溶離液:150mMのNaClを含む10mM phosphate buffer(pH 7.4))に供したところ、分子量が8万〜100万の範囲にポリペプチドのピークが認められた。分子量はアマシャム・バイオサイエンス(株)製のGel Filtration HMW Calibration Kitを標準物質として使用し、算出した。 The obtained polypeptide (IId) was subjected to gel permeation chromatography (Amersham Biosciences, AKTApurifier system, column: Superose 6 HR GL, flow rate: 0.5 mL / min, eluent: 10 mM containing 150 mM NaCl. When subjected to phosphate buffer (pH 7.4)), a polypeptide peak was observed in the molecular weight range of 80,000 to 1,000,000. The molecular weight was calculated using a Gel Filtration HMW Calibration Kit manufactured by Amersham Biosciences as a standard substance.
得られたポリペプチド(IId)の円二色性スペクトルを測定したところ、224nmに正のコットン効果、197nmに負のコットン効果が観測され、3重らせん構造を形成していることが確認された。 When the circular dichroism spectrum of the obtained polypeptide (IId) was measured, a positive cotton effect was observed at 224 nm and a negative cotton effect was observed at 197 nm, confirming the formation of a triple helical structure. .
実施例1(化粧水)
製造例7で得られたポリペプチド(Ih)を凍結乾燥することにより粉末状のポリペプチドを得た。このポリペプチド粉末0.1g、0.1gのポリエチレングリコール(PEG1500)、0.5gのプロピレングリコール、及び0.5gのグリセリンを、10mLの精製水に添加し、十分撹拌して、溶液を調製した。この溶液に、さらに1mLの1重量%パラベンのエタノール溶液を加え、十分撹拌した後、全体が20mLとなるように精製水で希釈することにより化粧水を調製した。
Example 1 (lotion)
The polypeptide (Ih) obtained in Production Example 7 was freeze-dried to obtain a powdery polypeptide. 0.1 g of this polypeptide powder, 0.1 g of polyethylene glycol (PEG 1500), 0.5 g of propylene glycol, and 0.5 g of glycerin were added to 10 mL of purified water and stirred well to prepare a solution. . To this solution was further added 1 mL of a 1 wt% paraben ethanol solution, and after sufficient stirring, a lotion was prepared by diluting with purified water so that the total amount was 20 mL.
実施例2(乳液)
実施例1と同様のポリペプチド粉末0.5g、プロピレングリコール5.0g、ポリエチレングリコール3.0g及びトリエタノールアミン1.0gを精製水70gに添加し、加熱して液温を70℃に調整し、水相を調製した。
Example 2 (milky lotion)
0.5 g of the same polypeptide powder as in Example 1, 5.0 g of propylene glycol, 3.0 g of polyethylene glycol and 1.0 g of triethanolamine were added to 70 g of purified water and heated to adjust the liquid temperature to 70 ° C. A water phase was prepared.
ステアリン酸2.0g、セチルアルコール1.0g、ワセリン2.0g、スクワラン5.0g及びグリセロールトリ−2−エチルヘキサン酸エステル2.0gの混合物を75℃に加熱して溶解し、さらにソルビタンモノオレイン酸エステル2.0g及びパラベン0.1gを添加した。得られた混合物の温度を70℃に調整し、油相を調製した。 A mixture of 2.0 g of stearic acid, 1.0 g of cetyl alcohol, 2.0 g of petrolatum, 5.0 g of squalane and 2.0 g of glycerol tri-2-ethylhexanoate is dissolved by heating to 75 ° C., and sorbitan monoolein 2.0 g of acid ester and 0.1 g of paraben were added. The temperature of the obtained mixture was adjusted to 70 ° C. to prepare an oil phase.
前記油相を前記水相に加えて撹拌、混合した後、さらにホモミキサーで乳化粒子を均一にし、脱気及びろ過を行い、ろ液を冷却することにより乳液を得た。 The oil phase was added to the aqueous phase and stirred and mixed. The emulsion particles were further homogenized with a homomixer, deaerated and filtered, and the filtrate was cooled to obtain an emulsion.
実施例3(保湿美容液)
実施例1と同様のポリペプチド粉末0.4g、ソルビトール1.6g、プロピレングリコール1.0g及びポリエチレングリコール(PEG1500)1.4gを精製水14gに添加し、水溶液を調製した。
Example 3 (Moisturizing serum)
0.4 g of the same polypeptide powder as in Example 1, 1.6 g of sorbitol, 1.0 g of propylene glycol and 1.4 g of polyethylene glycol (PEG 1500) were added to 14 g of purified water to prepare an aqueous solution.
別途、エタノール1.4gに、ポリオキシエチレンオレイルアルコールエーテル0.2g、オリーブ油40mg、及びパラベン20mgを添加してエタノール溶液を調製した。このエタノール溶液に、前記水溶液を添加して混合し、美容液を調製した。 Separately, 0.2 g of polyoxyethylene oleyl alcohol ether, 40 mg of olive oil, and 20 mg of paraben were added to 1.4 g of ethanol to prepare an ethanol solution. The aqueous solution was added to the ethanol solution and mixed to prepare a cosmetic solution.
実施例4(ハンドクリーム)
実施例1と同様のポリペプチド粉末0.5g、グリセリン15.0g、プロピレングリコール3.0g及び水酸化カリウム0.2gを精製水66.2gに溶解し、加熱して液温を70℃に調整し、水相を調製した。
Example 4 (hand cream)
The same polypeptide powder 0.5 g as in Example 1, 15.0 g of glycerin, 3.0 g of propylene glycol and 0.2 g of potassium hydroxide were dissolved in 66.2 g of purified water and heated to adjust the liquid temperature to 70 ° C. And an aqueous phase was prepared.
ステアリン酸3.0g、ステアリン酸モノグリセリド3.0g、ワセリン3.0g、流動パラフィン6.0g及びパラベン0.1gを混合し、加熱して、混合物の温度を70℃に調整し、油相を調製した。 Prepare 3.0 g of stearic acid, 3.0 g of stearic acid monoglyceride, 3.0 g of petrolatum, 6.0 g of liquid paraffin and 0.1 g of paraben and adjust the temperature of the mixture to 70 ° C. to prepare an oil phase. did.
この油相を前記水相に添加し、撹拌混合した後、ホモミキサーで乳化粒子を均一にし、脱気及びろ過を行った。得られたろ液を冷却することによりハンドクリームを得た。 This oil phase was added to the aqueous phase, and after stirring and mixing, the emulsified particles were made uniform with a homomixer, and deaerated and filtered. The obtained filtrate was cooled to obtain a hand cream.
Claims (9)
[-(OC-(CH2)m-CO)p-(Pro-Y-Gly)n-]a (1)
[-(OC-(CH2)m-CO)q-(Z)r-]b (2)
[-HN-R-NH-]c (3)
(式中、mは1〜18の整数、p及びqは同一又は異なって0又は1、YはProまたはHypを表し、nは1〜20の整数を表す。Zは1〜10個のアミノ酸残基からなるペプチド鎖を表し、rは1〜20の整数を表し、Rは直鎖状又は分岐鎖状アルキレン基を表す。aとbとの割合(モル比)はa/b=100/0〜30/70であり、p=1及びq=0であるときc=a、p=0及びq=1であるときc=bであり、p=1及びq=1であるときc=a+bであり、p=0及びq=0であるときc=0である。)
-Pro-Y-Gly- (4)
(式中、Yは前記に同じ)
-Pro-V-Gly-W-Ala-Gly- (5)
(式中、VはGln、Asn、Leu、Ile、ValまたはAla、WはIleまたはLeuを表す。) The polypeptide is a polypeptide (I) composed of peptide units represented by the following formulas (1) to (3), a peptide unit having an amino acid sequence represented by the following formula (4), and the following formula ( The cosmetic according to claim 1, which is at least one polypeptide selected from polypeptides (II) comprising a peptide unit having the amino acid sequence represented by 5).
[-(OC- (CH 2 ) m -CO) p- (Pro-Y-Gly) n- ] a (1)
[-(OC- (CH 2 ) m -CO) q- (Z) r- ] b (2)
[-HN-R-NH-] c (3)
(In the formula, m is an integer of 1 to 18, p and q are the same or different and 0 or 1, Y represents Pro or Hyp, n represents an integer of 1 to 20. Z represents 1 to 10 amino acids. Represents a peptide chain comprising residues, r represents an integer of 1 to 20, R represents a linear or branched alkylene group, and the ratio (molar ratio) between a and b is a / b = 100 / 0 = 30/70, c = 1 when p = 1 and q = 0, c = b when p = 0 and q = 1, c = when p = 1 and q = 1 a + b, c = 0 when p = 0 and q = 0.)
-Pro-Y-Gly- (4)
(Where Y is the same as above)
-Pro-V-Gly-W-Ala-Gly- (5)
(In the formula, V represents Gln, Asn, Leu, Ile, Val or Ala, and W represents Ile or Leu.)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003293045A JP2005060314A (en) | 2003-08-13 | 2003-08-13 | Cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003293045A JP2005060314A (en) | 2003-08-13 | 2003-08-13 | Cosmetic |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007178251A Division JP2007262087A (en) | 2007-07-06 | 2007-07-06 | Cosmetic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2005060314A true JP2005060314A (en) | 2005-03-10 |
Family
ID=34370166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003293045A Pending JP2005060314A (en) | 2003-08-13 | 2003-08-13 | Cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2005060314A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008075589A1 (en) * | 2006-12-21 | 2008-06-26 | Chisso Corporation | Substance capable of inducing platelet aggregation |
| WO2009035092A1 (en) * | 2007-09-13 | 2009-03-19 | National University Corporation NARA Institute of Science and Technology | Novel polypeptide and production method thereof |
| EP2103424A1 (en) | 2008-03-19 | 2009-09-23 | Chisso Corporation | Strechable laminated sheet |
| JP2010163386A (en) * | 2009-01-15 | 2010-07-29 | Chisso Corp | Cosmetic sheet |
| WO2010088469A2 (en) | 2009-01-30 | 2010-08-05 | Ethicon, Inc. | Collagen-related peptides and uses thereof and hemostatic foam substrates |
| US8076294B2 (en) | 2007-08-01 | 2011-12-13 | Advanced Technologies And Regenerative Medicine, Llc. | Collagen-related peptides and uses thereof |
| JP2014152167A (en) * | 2013-02-14 | 2014-08-25 | Hazel Thompson:Kk | Hair treatment agent |
| JP2016098203A (en) * | 2014-11-21 | 2016-05-30 | Jnc株式会社 | Hair cosmetic |
| JPWO2021020351A1 (en) * | 2019-07-29 | 2021-02-04 | ||
| WO2025133607A1 (en) * | 2023-12-21 | 2025-06-26 | Pplus Skin Care Limited | Collagen related peptide |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62138500A (en) * | 1985-12-11 | 1987-06-22 | Sumitomo Pharmaceut Co Ltd | Polypeptide production method |
| JPH04327600A (en) * | 1991-04-23 | 1992-11-17 | Asahi Glass Co Ltd | Peptide complex and pharmaceutical containing the complex as active component |
| JPH0543442A (en) * | 1991-08-14 | 1993-02-23 | Sansho Seiyaku Co Ltd | Skin cosmetic |
| JPH0925295A (en) * | 1995-06-06 | 1997-01-28 | Akzo Nobel Nv | Epstein-Barr virus peptide and antibodies to the peptide |
-
2003
- 2003-08-13 JP JP2003293045A patent/JP2005060314A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62138500A (en) * | 1985-12-11 | 1987-06-22 | Sumitomo Pharmaceut Co Ltd | Polypeptide production method |
| JPH04327600A (en) * | 1991-04-23 | 1992-11-17 | Asahi Glass Co Ltd | Peptide complex and pharmaceutical containing the complex as active component |
| JPH0543442A (en) * | 1991-08-14 | 1993-02-23 | Sansho Seiyaku Co Ltd | Skin cosmetic |
| JPH0925295A (en) * | 1995-06-06 | 1997-01-28 | Akzo Nobel Nv | Epstein-Barr virus peptide and antibodies to the peptide |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8981059B2 (en) | 2006-12-21 | 2015-03-17 | Jnc Corporation | Platelet aggregation inducing substance |
| WO2008075589A1 (en) * | 2006-12-21 | 2008-06-26 | Chisso Corporation | Substance capable of inducing platelet aggregation |
| JP5251516B2 (en) * | 2006-12-21 | 2013-07-31 | Jnc株式会社 | Platelet aggregation inducer |
| US8686117B2 (en) | 2006-12-21 | 2014-04-01 | Jnc Corporation | Platelet aggregation inducing substance |
| US8076294B2 (en) | 2007-08-01 | 2011-12-13 | Advanced Technologies And Regenerative Medicine, Llc. | Collagen-related peptides and uses thereof |
| WO2009035092A1 (en) * | 2007-09-13 | 2009-03-19 | National University Corporation NARA Institute of Science and Technology | Novel polypeptide and production method thereof |
| US8357774B2 (en) | 2007-09-13 | 2013-01-22 | National University Corporation NARA Institute of Science and Technology | Polypeptide and process for producing the same |
| EP2103424A1 (en) | 2008-03-19 | 2009-09-23 | Chisso Corporation | Strechable laminated sheet |
| JP2010163386A (en) * | 2009-01-15 | 2010-07-29 | Chisso Corp | Cosmetic sheet |
| WO2010088469A2 (en) | 2009-01-30 | 2010-08-05 | Ethicon, Inc. | Collagen-related peptides and uses thereof and hemostatic foam substrates |
| JP2014152167A (en) * | 2013-02-14 | 2014-08-25 | Hazel Thompson:Kk | Hair treatment agent |
| JP2016098203A (en) * | 2014-11-21 | 2016-05-30 | Jnc株式会社 | Hair cosmetic |
| JPWO2021020351A1 (en) * | 2019-07-29 | 2021-02-04 | ||
| WO2021020351A1 (en) * | 2019-07-29 | 2021-02-04 | 株式会社 資生堂 | Oily cosmetic |
| CN114173755A (en) * | 2019-07-29 | 2022-03-11 | 株式会社资生堂 | Oily cosmetic |
| CN114173755B (en) * | 2019-07-29 | 2024-02-06 | 株式会社资生堂 | Oily cosmetic |
| JP7455126B2 (en) | 2019-07-29 | 2024-03-25 | 株式会社 資生堂 | oil-based cosmetics |
| WO2025133607A1 (en) * | 2023-12-21 | 2025-06-26 | Pplus Skin Care Limited | Collagen related peptide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2801961C (en) | Skin antiaging treatment | |
| ES2621542T3 (en) | Peptides used in the treatment and / or care of skin, mucous membranes and / or hair and their use in cosmetic or pharmaceutical compositions | |
| US9315564B2 (en) | Cosmetic or pharmaceutical compositions comprising metalloproteinase inhibitors | |
| ES2639464T3 (en) | Useful compounds for the treatment and / or care of the skin and its cosmetic or pharmaceutical compositions | |
| KR101757946B1 (en) | Compounds which inhibit muscle contraction | |
| ES2733338T3 (en) | Peptides useful in the treatment and / or care of skin, mucous membranes, scalp and / or hair and their use in cosmetic or pharmaceutical compositions | |
| US20070207180A1 (en) | Synthetic polypeptide-containing bioapplicable material and film-forming material | |
| JP5781224B2 (en) | Peptide derivatives with excellent moisture retention and uses thereof | |
| CN103068844B (en) | Retinol modified collagen, its preparation method and the composition for external application containing it | |
| JP2013006810A (en) | Cosmetic for eyelash | |
| JP2005060314A (en) | Cosmetic | |
| JP2007262087A (en) | Cosmetic | |
| JPS62123198A (en) | Decapeptide | |
| JP2005060315A (en) | Pharmaceutical preparation composition | |
| JP6394320B2 (en) | Hair cosmetics | |
| JP4115361B2 (en) | Edible composition | |
| JP2007223981A (en) | Peptide stabilizers | |
| KR101553637B1 (en) | Peptide fatty acid derivative and cosmetic composition having anti-wrinkle activity containing the derivative | |
| JP6132299B2 (en) | Composition comprising collagen | |
| EP1908828A1 (en) | Novel polypeptide and method for producing the same | |
| JP2005126360A (en) | Collagenase inhibitor composed of new polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051018 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060628 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20060628 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060628 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20061016 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061121 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070110 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070508 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070709 |
|
| A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070713 |
|
| A912 | Removal of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20071207 |